0001558370-16-009291.txt : 20161104 0001558370-16-009291.hdr.sgml : 20161104 20161104090110 ACCESSION NUMBER: 0001558370-16-009291 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161104 DATE AS OF CHANGE: 20161104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GLYCOMIMETICS INC CENTRAL INDEX KEY: 0001253689 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36177 FILM NUMBER: 161973780 BUSINESS ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-243-1201 MAIL ADDRESS: STREET 1: 9708 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 10-Q 1 glyc-20160930x10q.htm 10-Q glyc_Current_Folio_10Q

accruedfranchiseandotherWeather

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 10-Q


 

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2016

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                       

 

Commission File Number 001-36177

 


 

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

 


 

Delaware

06-1686563

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

 

 

9708 Medical Center Drive

Rockville, Maryland

20850

(Address of principal executive offices)

(Zip Code)

 

(240) 243-1201

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 


 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ◻ 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ◻ 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Securities Exchange Act of 1934.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

◻  (Do not check if a smaller reporting company)

Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).    Yes  ◻    No   ☒ 

 

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, as of the close of business on November 3, 2016 was 23,065,131.

 

 

 


 

GLYCOMIMETICS, INC.

 

INDEX TO FORM 10-Q

 

 

 

 

 

 

PAGE

 

 

 

PART I. FINANCIAL INFORMATION 

 

 

 

 

 

Item 1. Financial Statements 

 

 

 

 

Balance Sheets as of September 30, 2016 (unaudited) and December 31, 2015 

 

 

 

 

Unaudited Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2016 and 2015 

 

 

 

 

Unaudited Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 

 

 

 

 

Notes to Unaudited Financial Statements 

 

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

16 

 

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk 

 

27 

 

 

 

Item 4. Controls and Procedures 

 

27 

 

 

 

PART II. OTHER INFORMATION 

 

 

 

 

 

Item 1. Legal Proceedings 

 

28 

 

 

 

Item 1A. Risk Factors 

 

28 

 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 

 

28 

 

 

 

Item 6. Exhibits 

 

29 

 

 

 

Signatures 

 

30 

 

 

 

2


 

Part I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

GLYCOMIMETICS, INC.

Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

 

2016

 

2015

 

Assets

    

(Unaudited)

    

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

45,282,550

 

$

46,802,560

 

Prepaid expenses and other current assets

 

 

1,239,716

 

 

441,810

 

Total current assets

 

 

46,522,266

 

 

47,244,370

 

Property and equipment, net

 

 

676,593

 

 

521,378

 

Deposits

 

 

52,320

 

 

 —

 

Prepaid research and development expenses

 

 

759,531

 

 

696,531

 

Total assets

 

$

48,010,710

 

$

48,462,279

 

Liabilities & stockholders’ equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

1,246,739

 

$

564,235

 

Accrued bonuses

 

 

826,455

 

 

1,037,112

 

Accrued expenses

 

 

3,263,359

 

 

6,145,631

 

Deferred rent

 

 

81,398

 

 

 —

 

Total current liabilities

 

 

5,417,951

 

 

7,746,978

 

Deferred rent, net of current portion

 

 

841,426

 

 

243,647

 

Total liabilities

 

 

6,259,377

 

 

7,990,625

 

Stockholders’ equity:

 

 

 

 

 

 

 

Preferred Stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2016 and December 31, 2015

 

 

 

 

 

Common stock; $0.001 par value; 100,000,000 shares authorized, 23,063,430 shares issued and outstanding at September 30, 2016; 100,000,000 shares authorized, 19,050,204 shares issued and outstanding at December 31, 2015

 

 

23,062

 

 

19,049

 

Additional paid-in capital

 

 

152,375,985

 

 

127,619,078

 

Accumulated deficit

 

 

(110,647,714)

 

 

(87,166,473)

 

Total stockholders’ equity

 

 

41,751,333

 

 

40,471,654

 

Total liabilities and stockholders’ equity

 

$

48,010,710

 

$

48,462,279

 

 

The accompanying notes are an integral part of the unaudited financial statements.

 

3


 

 

GLYCOMIMETICS, INC.

Unaudited Statements of Operations and Comprehensive Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

2016

 

2015

 

2016

 

2015

Revenue

    

$

18,500

    

$

 —

    

$

18,500

    

$

20,035,375

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

5,921,461

 

 

5,038,380

 

 

17,221,360

 

 

18,088,994

General and administrative expense

 

 

1,983,795

 

 

2,132,993

 

 

6,352,355

 

 

5,843,680

Total costs and expenses

 

 

7,905,256

 

 

7,171,373

 

 

23,573,715

 

 

23,932,674

Loss from operations

 

 

(7,886,756)

 

 

(7,171,373)

 

 

(23,555,215)

 

 

(3,897,299)

Other income

 

 

32,063

 

 

3,302

 

 

73,974

 

 

9,504

Net loss and comprehensive loss

 

$

(7,854,693)

 

$

(7,168,071)

 

$

(23,481,241)

 

$

(3,887,795)

Basic and diluted net loss per common share

 

$

(0.34)

 

$

(0.38)

 

$

(1.14)

 

$

(0.20)

Basic and diluted weighted average number of common shares

 

 

23,049,347

 

 

19,025,623

 

 

20,638,129

 

 

18,999,705

 

The accompanying notes are an integral part of the unaudited financial statements.

 

4


 

GLYCOMIMETICS, INC.

Unaudited Statements of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 

 

 

 

2016

 

2015

 

Operating activities

    

 

 

    

 

 

    

Net loss

 

$

(23,481,241)

 

$

(3,887,795)

 

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation

 

 

139,749

 

 

142,417

 

Loss on disposal of property and equipment

 

 

 —

 

 

8,001

 

Stock-based compensation expense

 

 

2,238,647

 

 

1,678,668

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(797,906)

 

 

198,015

 

Prepaid research and development expenses

 

 

(63,000)

 

 

 —

 

Deposits

 

 

(52,320)

 

 

 —

 

Accounts payable

 

 

682,504

 

 

(240,935)

 

Accrued expenses

 

 

(3,122,258)

 

 

727,701

 

Deferred rent

 

 

679,177

 

 

89,514

 

Net cash used in operating activities

 

 

(23,776,648)

 

 

(1,284,414)

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(265,635)

 

 

(265,367)

 

Net cash used in investing activities

 

 

(265,635)

 

 

(265,367)

 

 

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net of issuance costs

 

 

22,453,785

 

 

 —

 

Proceeds from exercise of stock options

 

 

68,488

 

 

110,697

 

Net cash provided by financing activities

 

 

22,522,273

 

 

110,697

 

Net change in cash and cash equivalents

 

 

(1,520,010)

 

 

(1,439,084)

 

Cash and cash equivalents, beginning of period

 

 

46,802,560

 

 

55,198,923

 

Cash and cash equivalents, end of period

 

$

45,282,550

 

$

53,759,839

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash investing activities:

 

 

 

 

 

 

 

Property asset acquisition included in accounts payable and accrued expenses

 

$

29,329

 

$

 —

 

 

The accompanying notes are an integral part of the unaudited financial statements.

 

5


 

GLYCOMIMETICS, INC.

Notes to Unaudited Financial Statements

 

1. Description of the Business

 

GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April 4, 2003 and commenced operations on May 21, 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

 

The Company’s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates or commenced commercial operations. The Company is subject to a number of risks similar to those of other companies in similar development stages, including dependence on key individuals, the need to develop commercially viable drugs, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its drug candidates. The Company has incurred significant operating losses since inception and has relied on its ability to fund its operations through private and public equity financings, and management expects operating losses and negative operating cash flows to continue for the foreseeable future. As the Company continues to incur losses, profitability will be dependent upon the successful development, approval, and commercialization of its drug candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. Management intends to fund future operations through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources.

 

2. Significant Accounting Policies

 

Basis of Accounting

 

The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).

 

Unaudited Financial Statements

 

The accompanying balance sheet as of September 30, 2016 and statements of operations and comprehensive loss for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2015 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 29, 2016. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015. The December 31, 2015 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2016 and 2015 are unaudited. Interim results are not necessarily indicative of results for an entire year.

 

6


 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

 

Fair Value Measurements

 

The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of September 30, 2016 and December 31, 2015. The carrying value of cash held in money market funds of approximately $44.1 million and $45.5 million as of September 30, 2016 and December 31, 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).

 

Concentration of Credit Risk

 

Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of money market funds with major financial institutions in the United States. These funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.

 

Revenue Recognition

 

From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements.

 

The Company has entered into a collaborative research and development agreement with Pfizer Inc. (Pfizer). The agreement is in the form of a license agreement (the Pfizer Agreement). The Pfizer Agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The Pfizer Agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the Pfizer Agreement that contain material financial consequences to the Company.

 

The primary deliverable under this arrangement is an exclusive worldwide license to the Company’s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer’s behalf.

 

Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of Accounting Standards Codification (ASC) 605-25, Revenue Recognition—Multiple-Element Arrangements, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis and (2) if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i) vendor-specific objective evidence (VSOE), if available; (ii) third-party evidence (TPE) of selling price if VSOE is not available; or (iii) an estimated selling price, if neither VSOE nor TPE is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering into such arrangements or selling the individual deliverables within

7


 

such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer Agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company’s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data.

 

Pursuant to ASC 605-25, each required deliverable under the Pfizer Agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company’s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company’s technology and the related proprietary nature of the Company’s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the Pfizer Agreement and will be combined with the research and development services (including participation on a joint steering committee).

 

As such, the $22.5 million up-front payment received was recognized as revenue over the expected development period through March 2013. The determination of the length of the period over which to defer revenue and the methodology by which to recognize the related revenues is subject to judgment and estimation. Consistent with the research plan developed by and agreed to by both parties, management estimated that the research activities and participation on the joint steering committees would occur over a 1.5-year period. Revenues associated with the up-front license fee were recognized over this period using a straight-line method, which was consistent with expected completion of the research services. The research services were completed in March 2013, consistent with the expected development period.

 

Pursuant to ASC 605-28, Revenue Recognition—Milestone Method, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement.

 

Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment.

 

Accrued Liabilities

 

The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical

8


 

materials. Pursuant to the Company’s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company’s judgment.

 

Research and Development Costs

 

Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.

 

Stock-Based Compensation

 

Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.

 

The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.

 

A discussion of management’s methodology for developing some of the assumptions used in the valuation model follows:

 

Expected Dividend Yield—The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

 

Expected Volatility—Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company’s initial public offering, there was not a market for the Company’s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company’s historical volatility since its initial public offering, to determine its expected volatility.

 

Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.

 

Expected Term—This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.

 

Expected Forfeiture Rate—The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.

 

Equity instruments issued to nonemployees are accounted for under the provisions of ASC 718, Compensation—Stock Compensation, and ASC 505-50, Equity—Equity-Based Payments to Non-Employees. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services are completed and are marked to market during the service period.

 

9


 

Net Loss Per Common Share

 

Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock options, restricted stock units and warrants.

 

Basic and diluted net loss per common share is computed as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

    

2016

 

2015

    

Net loss

 

$

(7,854,693)

 

$

(7,168,071)

 

$

(23,481,241)

 

$

(3,887,795)

 

Basic and diluted net loss per common share

 

$

(0.34)

 

$

(0.38)

 

$

(1.14)

 

$

(0.20)

 

Basic and diluted weighted average common shares outstanding

 

 

23,049,347

 

 

19,025,623

 

 

20,638,129

 

 

18,999,705

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

    

2015

    

2016

    

2015

    

Warrants

 

555,412

 

590,595

 

555,412

 

590,595

 

Stock options and restricted stock units

 

2,815,166

 

2,250,008

 

2,815,166

 

2,250,008

 

 

Comprehensive Loss

 

Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and nine months ended September 30, 2016 and 2015, the Company’s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.  

 

3. Prepaid Expenses and Other Current Assets

 

The following is a summary of the Company’s prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Prepaid expenses

 

$

667,644

 

$

393,857

 

Other receivables

 

 

572,072

 

 

38,683

 

Deposits

 

 

 —

 

 

9,270

 

Prepaid expenses and other current assets

 

$

1,239,716

 

$

441,810

 

 

 

10


 

4. Property and Equipment

 

Property and equipment, net consists of the following:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Furniture and fixtures

 

$

230,987

 

$

230,987

 

Laboratory equipment

 

 

978,511

 

 

965,586

 

Office equipment

 

 

9,723

 

 

9,723

 

Computer equipment

 

 

186,172

 

 

181,053

 

Leasehold improvements

 

 

36,128

 

 

36,128

 

Construction in progress

 

 

271,355

 

 

 —

 

Property and equipment

 

 

1,712,876

 

 

1,423,477

 

Less accumulated depreciation

 

 

(1,036,283)

 

 

(902,099)

 

Property and equipment, net

 

$

676,593

 

$

521,378

 

Depreciation expense was $45,808 and $51,882 for the three months ended September 30, 2016 and 2015, respectively, and $139,749 and $142,417 for the nine months ended September 30, 2016 and 2015, respectively.

 

5. Accrued Expenses

 

The following is a summary of the Company’s accrued expenses:

 

 

 

 

 

 

 

 

 

 

    

September 30, 

    

December 31, 

 

 

 

2016

 

2015

 

Accrued research and development expenses

 

$

2,323,255

 

$

3,423,220

 

Accrued license and milestone fees

 

 

 —

 

 

2,000,000

 

Accrued consulting and other professional fees

 

 

263,211

 

 

242,227

 

Other accrued expenses

 

 

327,018

 

 

281,152

 

Accrued employee benefits

 

 

349,875

 

 

195,442

 

Accrued franchise and other taxes

 

 

 —

 

 

3,590

 

Accrued expenses

 

$

3,263,359

 

$

6,145,631

 

 

 

 

 

6. Operating Leases

 

The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease.

 

In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance reflected in the Company’s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company’s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company’s renewal option set forth in the Lease. The Company’s one-time option to terminate the Lease effective as of October 31, 2020 also applies to the additional space.

 

Deferred rent related to the Lease was $922,824 and $243,647 at September 30, 2016 and December 31, 2015, respectively. Total rent expense under the Company’s operating leases was $219,983 and $216,765 for the three months

11


 

ended September 30, 2016 and 2015, respectively, and $557,262 and $437,125 for the nine months ended September 30, 2016 and 2015, respectively.

 

 

 

7. Stockholders’ Equity

 

At-The-Market Equity Offering

 

On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company’s securities under a shelf registration statement filed in March 2015. As of September 30, 2016, the Company had issued and sold 483,298 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.296, for aggregate net proceeds of $2.7 million, after deducting commissions and offering expenses.

 

Equity Offering

 

In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share. The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.

 

2003 Stock Incentive Plan

 

The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60 days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May 21, 2013.

 

A summary of the Company’s stock option activity under the 2003 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

 

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

    

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

758,187

 

$

1.27

 

4.2

 

 

 

 

Options exercised

 

(27,268)

 

 

1.49

 

 

 

 

 

 

Options forfeited

 

 —

 

 

 —

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

730,919

 

 

1.26

 

3.5

 

$

4,306

 

Vested or expected to vest as of September 30, 2016

 

730,888

 

 

1.26

 

3.5

 

$

4,306

 

Exercisable as of September 30, 2016

 

729,565

 

 

1.25

 

3.5

 

$

4,301

 

 

As of September 30, 2016, there was $2,991 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over a weighted-average period less than one year. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 and 2015 was $95,221 and $699,196, respectively, and total cash received for options exercised was $40,668 and $110,697 during the nine months ended September 30, 2016 and 2015, respectively. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $14,450 and $38,223, respectively.

 

12


 

2013 Equity Incentive Plan

 

The Company’s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to the Company’s employees and its parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company’s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.

 

Authorized Shares

 

The maximum number of shares of common stock that initially could be issued under the 2013 Plan was  1,000,000 shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan automatically increases on January 1 of each year until January 1, 2023, by 3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January 1, 2016, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 571,506 shares, representing 3% of the total number of shares of common stock outstanding on December 31, 2015, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,139,701 shares.

 

Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.

 

A summary of the Company’s stock option activity under the 2013 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

ccc

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

 

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

1,470,338

 

$

8.26

 

8.5

 

 

 

 

Options granted

 

618,250

 

 

5.35

 

 

 

 

 

 

Options exercised

 

(3,500)

 

 

7.95

 

 

 

 

 

 

Options forfeited

 

(22,591)

 

 

6.20

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

2,062,497

 

 

7.41

 

8.2

 

$

1,110

 

Vested or expected to vest as of September 30, 2016

 

2,053,321

 

 

7.41

 

8.2

 

$

1,100

 

Exercisable as of September 30, 2016

 

828,814

 

 

8.26

 

7.7

 

$

1

 

 

13


 

The weighted-average fair value of the options granted during the nine months ended September 30, 2016 and 2015 was $3.38 per share and $5.09 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:

 

 

 

 

 

 

 

 

Nine Months Ended

 

Nine Months Ended

 

    

September 30, 2016

 

September 30, 2015

Expected term

 

6.25 years

 

6.25 years

Expected volatility

 

68.86%

 

80.83%

Risk-free interest rate

 

1.69%

 

1.70%

Expected dividend yield

 

0%

 

0%

 

As of September 30, 2016, there was $5,014,309 of total unrecognized compensation expense related to unvested options under the 2013 Plan that will be recognized over a weighted-average period of approximately 2.2 years. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 was $2,275 and total cash received for options exercised was $27,825 during the nine months ended September 30, 2016. There were no options exercised during the nine months ending September 30, 2015. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $2,364,683 and $2,314,557, respectively.

 

A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of September 30, 2016, there was $70,027 of unrecognized compensation costs related to unvested service RSUs.

 

The following is a summary of RSU activity under the 2013 Plan for the nine months ended September 30, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

NUMBER

 

GRANT DATE

 

 

    

OF SHARES

 

 

FAIR VALUE

 

Unvested at December 31, 2015

 

 

4,833

 

$

7.62

 

Granted

 

 

14,500

 

 

4.61

 

Forfeited

 

 

 —

 

 

 —

 

Vested

 

 

 —

 

 

 —

 

Unvested at September 30, 2016

 

 

19,333

 

 

5.36

 

 

Stock-based compensation expense was classified on the statement of operations as follows for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

   

2016

 

2015

    

Research and development expense

 

$

260,882

 

$

209,359

 

$

772,163

 

$

590,633

 

General and administrative expense

 

 

478,531

 

 

423,565

 

 

1,466,484

 

 

1,088,035

 

Total stock-based compensation expense

 

$

739,413

 

$

632,924

 

$

2,238,647

 

$

1,678,668

 

 

Warrants to Acquire Common Stock

 

During the three months ended September 30, 2016, 22,367 shares of common stock were issued to an existing stockholder upon the net exercise of a warrant. No warrants were exercised during the three months ended September 30, 2015.  No warrants expired during the three months ended September 30, 2016 and 2015.

 

 

 

 

 

 

 

14


 

8. Income Taxes

 

The Company has not recorded any tax provision or benefit for the nine months ended September 30, 2016 and 2015. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at September 30, 2016 and December 31, 2015.

 

9. Research and License Agreements

 

In October 2011, the Company and Pfizer entered into the Pfizer Agreement that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 clinical trial, after which Pfizer assumed all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Agreement by giving prior written notice.

 

The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-front payment was recognized over a period of 1.5 years. In May 2014, Pfizer made a $15.0 million non-refundable milestone payment to the Company, which was recognized as revenue by the Company in May 2014 when earned.  In June 2015, Pfizer dosed the first patient in the Phase 3 clinical trial of rivipansel, which triggered a non-refundable milestone payment to the Company of $20.0 million, which the Company recognized as revenue in June 2015.

 

In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe to the University 10% of all future milestone and royalty payments received from Pfizer with respect to rivipansel.  As of December 31, 2015, a $2.0 million milestone license fee was recorded as an accrued liability representing 10% of the $20.0 million non-refundable milestone payment that the Company received from Pfizer in 2015.  The accrued liability of $2.0 million was paid in February 2016.

 

15


 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions, or the negative of such words or phrases, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those below and elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K, particularly in Part I – Item 1A, “Risk Factors,” and our other filings with the Securities and Exchange Commission. Statements made herein are as of the date of the filing of this Form 10-Q with the Securities and Exchange Commission and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December 31, 2015, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2016.

 

Overview

 

We are a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases.

We are focusing our initial efforts on drug candidates for rare diseases that we believe will qualify for orphan drug designation. Our first drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis, or VOC, one of the most severe complications of sickle cell disease. We have entered into a collaboration with Pfizer Inc., or Pfizer, for the further development and potential commercialization of rivipansel worldwide. Rivipansel has received fast track designation from the U.S. Food and Drug Administration, or FDA, as well as orphan drug designation from the FDA in the United States and from the European Medicines Agency in the European Union. We believe the clinical progress of rivipansel provides evidence of the significant potential of our lead program and our proprietary glycomimetics platform.

Building on our experience with rivipansel, we are developing a pipeline of other glycomimetic drug candidates. Our second glycomimetic drug candidate, GMI-1271, is a specific E-selectin inhibitor, which we are developing to be used in combination with chemotherapy to treat patients with either acute myeloid leukemia, or AML, or multiple myeloma, or MM, both of which are life-threatening hematologic cancers, and potentially other hematologic cancers as well. GMI-1271 received orphan drug designation in AML from the FDA in May 2015. In June 2016, GMI-1271 received fast track designation for the treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML. We are currently conducting clinical trials in both AML and MM.

In May 2015, we commenced a multinational, Phase 1/2, open-label trial of GMI-1271 as an adjunct to standard chemotherapy in patients with AML. The trial consists of two parts. In the Phase 1 portion, dose escalation testing was performed to determine a recommended GMI-1271 dose in combination with standard chemotherapy for the Phase 2 portion. The primary objective of this portion of the trial was to evaluate the safety of GMI-1271 in combination with

16


 

chemotherapy. Secondary objectives were to characterize pharmacokinetics, or PK, and pharmacodynamics, and to observe anti-leukemic activity.  There were a total of 19 patients enrolled and dosed with GMI-1271 and chemotherapy in the Phase 1 portion of the trial. Patients had relapsed or refractory AML and other risk factors indicating poor prognosis.

In the Phase 1 portion of the trial, the combination of GMI-1271 and chemotherapy was well-tolerated, with no dose-limiting toxicities observed and no mortality reported during the treatment phase of 44 days. Serious adverse events, including sepsis, pneumonia, device-related infection, enterocolitis, hypernatremia and adjustment disorder, were observed in five patients, with all such events resolving during the treatment phase. Fourteen of the 19 patients were not noted to have mucositis after chemotherapy was completed, which often develops following treatment with this intensive therapy.

In terms of efficacy, eight of the 19 patients achieved complete remission, with a full bone marrow response, or CR, and full blood count recovery. One additional patient achieved CR but with an incomplete blood count recovery prior to receiving a hematopoietic stem cell transplant, or HSCT, a response referred to as CRi. The total of nine patients achieving remission represents an overall response rate of 47%. Standard high-dose chemotherapy regimens for relapsed/refractory AML patients typically have remission rates of between 25-30%. One additional patient achieved a status known as morphologic leukemia-free state, which is not included in the overall response rate. Five patients who achieved remission proceeded to receiving an HSCT. PK data showed a dose-dependent increase in plasma concentrations of GMI-1271, such that all were above levels associated with anti-leukemic activity in animal models of AML. In addition, biomarker analysis showed a biological on-target effect of GMI-1271 at all dose levels.

With an optimal dose of 10 mg/kg having been determined for the remainder of the trial, in June 2016, we dosed the first patient in the Phase 2 portion of the trial. In this portion of the trial, dose-expansion testing will be conducted to obtain additional safety and efficacy data in two defined sub-populations of AML. One arm of the trial will enroll relapsed or refractory AML patients; the second arm will enroll patients over 60 years of age with newly diagnosed AML. We expect to enroll a total of approximately 50 patients in the Phase 2 portion of the trial. Unlike in the Phase 1 portion, some of the patients in the Phase 2 portion may be treated with multiple cycles of GMI-1271. The Phase 2 portion of the trial is being conducted in the United States, Ireland and Australia.

In September 2016, we dosed the first patient in a Phase 1 clinical trial of GMI-1271 combined with bortezomib-based chemotherapy, for the treatment of MM. The newly initiated multi-center, open-label dose escalation trial, which has begun in Ireland, will measure the efficacy, safety and pharmacokinetics of GMI-1271 in combination with chemotherapy among patients who have been diagnosed with MM and have not responded optimally to standard chemotherapy. We anticipate enrolling 24 participants in the trial. In the Phase 1 study, participants will include individuals who have been diagnosed with MM and undergone bortezomib-based therapy with inadequate responses. The patients will receive one of four doses of GMI-1271 in combination with bortezomib, intravenously concurrently throughout treatment cycle. They will be followed after treatment to measure safety endpoints and efficacy.

We are also collaborating with the University of Michigan to evaluate GMI-1271 as a potential new class of anticoagulant to treat persons at risk for venous thromboembolic disease, a serious blood-clotting disorder. The University of Michigan began dosing healthy volunteers in a Phase 1 clinical trial of GMI-1271 in December 2014. The Phase 1 clinical trial is a randomized, partially blinded, active placebo-controlled trial for which we completed initial enrollment in October 2015. The trial design has subsequently been amended to include a multiple ascending dose portion, which was fully enrolled as of March 2016 and all subjects have completed dosing. As a follow-up to the multiple ascending dose study, the University of Michigan is launching a Phase 1/2 study to evaluate the safety, tolerability and efficacy of GMI-1271 in patients with calf-level deep vein thrombosis. This study began in the third quarter of 2016 and is expected to complete enrollment in the fourth quarter of 2016.

We are also developing a pipeline of other preclinical drug candidates based on our expertise in carbohydrate chemistry. We have designed a family of small molecule drug candidates that simultaneously inhibit both E-selectin and CXCR4. We have selected one of these compounds, GMI-1359, to be developed further as part of an IND-enabling nonclinical program. We intend to develop GMI-1359 as a potential treatment for hematologic malignancies. Since E-

17


 

selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone marrow such as AML and MM, as compared to targeting CXCR4 alone. In December 2015 at the annual meeting of the American Society of Hematology, we presented preclinical data suggesting that GMI-1359 may enhance the ability of chemotherapy to target and improve survival rates in patients with a high-risk form of mutated AML.

In August 2016, we dosed the first participant in a Phase 1 single-dose escalation trial of GMI-1359 in healthy volunteers.  In this first-in-humans trial, volunteer participants will receive a single injection of GMI-1359, after which the patients will be evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics over 16 days. The randomized, double-blind placebo controlled escalating dose study is being conducted at a single site in the United States.

Using our glycomimetics platform, we have designed galectin-3 and galectin-9 inhibitors that specifically block the binding of galectin-3 and galectin-9 to carbohydrate structures.  Galectin-3 and galectin-9 are proteins that are known to play critical roles in many pathological processes, including checkpoints in T-cell exhaustion during cancer immunotherapy, chemotherapy resistance, fibrosis and cardiovascular disease. We plan to optimize these compounds and conduct preclinical experiments in 2017 to further characterize the effects of galectin-3 and galectin-9 inhibitors on immune processes and anti-fibrotic activity.

We commenced operations in 2003, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our glycomimetics platform, identifying potential drug candidates, undertaking preclinical studies and conducting clinical trials of rivipansel, GMI-1271 and GMI-1359. To date, we have financed our operations primarily through private placements of our securities, upfront and milestone payments under our collaboration with Pfizer, the net proceeds from our IPO in January 2014, net proceeds from our at-the-market facility with Cowen and Company LLC, or Cowen, and net proceeds from our public offering of common stock in June 2016. We have no approved drugs currently available for sale, and substantially all of our revenue to date has been revenue from the upfront and milestone payments from Pfizer, although we have received nominal amounts of revenue under research grants. Prior to our IPO, we raised an aggregate of $86.6 million to fund our operations, of which $22.5 million was an upfront payment under our collaboration with Pfizer and $64.1 million was from the sale of our convertible promissory notes and convertible preferred stock. The IPO provided us with net proceeds of $57.2 million, and we received a non-refundable milestone payment from Pfizer in May 2014 of $15.0 million. In August 2015, we received another non-refundable milestone payment from Pfizer of $20.0 million following the dosing of the first patient in the Phase 3 clinical trial of rivipansel. In 2016, we received an additional $19.7 million of net proceeds from our public offering in June 2016 and $2.7 million of net proceeds under the at-the-market facility with Cowen.

Since inception, we have incurred significant operating losses. Although we have generated cumulative revenue of $58.6 million since our inception through September 30, 2016, primarily consisting of the $22.5 million upfront payment from Pfizer in 2011, the $15.0 million non-refundable milestone payment in May 2014 and the $20.0 million non-refundable milestone payment in August 2015, we had an accumulated deficit of $110.6 million as of September 30, 2016, and we expect to continue to incur significant expenses and operating losses over at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials, the receipt of milestone payments, if any, under our collaboration with Pfizer, and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:

·

conduct our clinical trials of GMI-1271 and prepare to potentially submit an application for marketing approval;

·

conduct earlier-stage clinical trials of GMI-1359;

·

continue the research and development of our other drug candidates;

·

seek to discover and develop additional drug candidates;

·

seek regulatory approvals for any drug candidates other than rivipansel that successfully complete clinical trials;

18


 

·

ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates other than rivipansel for which we may obtain regulatory approval;

·

maintain, expand and protect our intellectual property portfolio;

·

hire additional clinical, quality control and scientific personnel; and

·

add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.

 

To fund further operations, we will need to raise capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. 

We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan. Although it is difficult to predict future liquidity requirements, we believe that our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our operations through the second quarter of 2018. However, our ability to successfully transition to profitability will be dependent upon achieving a level of revenues adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.

Our Collaboration with Pfizer

In October 2011, we entered into the license agreement with Pfizer under which we granted Pfizer an exclusive worldwide license to develop and commercialize products containing rivipansel for all fields and uses. The license also covers specified back-up compounds along with modifications of and improvements to rivipansel that meet defined chemical properties. Pfizer is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize rivipansel for sickle cell disease in the United States. Under the terms of the agreement, we received a $22.5 million upfront payment. We are also eligible to earn potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties for each licensed product, with percentages ranging from the low double digits to the low teens, based on net sales worldwide, subject to reductions in specified circumstances.

 

The first potential milestone payment under the Pfizer agreement was $35.0 million upon the initiation of dosing of the first patient in a Phase 3 clinical trial of rivipansel by Pfizer. Under the collaboration, Pfizer made a $15.0 million non-refundable milestone payment to us in May 2014, which we recognized as revenue in May 2014, when earned, and the dosing of the first patient in the Phase 3 clinical trial in June 2015 triggered the remaining $20.0 million milestone payment to us. We recorded the $20.0 million milestone payment as revenue in June 2015. 

We have a research services agreement with the University of Basel, or the University, under which University personnel have performed research services for us on an as-requested basis since 2004. The agreement includes one-year research terms, and we have no affirmative obligation to purchase any minimum amount of services in any year beyond what we commit to at the beginning of each term, if any. For the research terms ended in February 2015 and 2016, we paid the University approximately $200,000 and $100,000, respectively. As part of the original consideration for entering into this agreement, we granted to the University the right to receive payments from us under specified circumstances. If we receive any future milestone payments or royalties from Pfizer with respect to rivipansel, we have agreed to pay 10% of those amounts to the University. As of December 31, 2015, we have recorded a $2.0 million liability to the University based upon the $20.0 million non-refundable milestone payment from Pfizer. In February 2016, we paid the $2.0 million accrued

19


 

liability to the University. During the three and nine months ended September 30, 2016, there were no additional milestone payments recorded in our statements of operations.

Critical Accounting Policies and Significant Judgments and Estimates

 

There have been no material changes in our critical accounting policies, estimates and judgments during the nine months ended September 30, 2016 compared to the disclosures in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2015.

 

Components of Operating Results

 

Revenue

 

To date, we have not generated any revenue from the sale of our drug candidates and do not expect to generate any revenue from the sale of drugs in the near future. Substantially all of our revenue recognized to date has consisted of the upfront and milestone payments under our agreement with Pfizer.

 

Since our inception, we have also recognized a nominal amount of revenue under research grant contracts, generally to the extent of our costs incurred in connection with specific research or development activities.

 

Research and Development

 

Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants and other outside expenses. Other preclinical research and platform programs include activities related to exploratory efforts, target validation, lead optimization for our earlier programs and our proprietary glycomimetics platform.

 

To date, our research and development expenses have related primarily to the development of rivipansel and our other drug candidates. In April 2013, when we completed our Phase 2 clinical trial of rivipansel, all further clinical development obligations associated with rivipansel shifted to Pfizer.

 

We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis because we are organized and record expense by functional department and our employees may allocate time to more than one development project. Accordingly, we only allocate a portion of our research and development expenses by functional area and by drug candidate.

 

Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

 

Research and development activities are central to our business model. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We expect our research and development expenses to increase over the next several years as we seek to progress GMI-1271, GMI-1359 and our other drug candidates through clinical development. For example, as we prepare to potentially submit an application for marketing approval for GMI-1271, we will incur substantial expenses in scaling up the production and manufacturing of GMI-1271. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical studies and clinical trials of our drug candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our drug candidates.

 

20


 

The duration, costs and timing of clinical trials and development of our drug candidates will depend on a variety of factors that include:

 

·

per patient trial costs;

 

·

the number of patients that participate in the trials;

 

·

the number of sites included in the trials;

 

·

the countries in which the trial is conducted;

 

·

the length of time required to enroll eligible patients;

 

·

the number of doses that patients receive;

 

·

the drop-out or discontinuation rates of patients;

 

·

potential additional safety monitoring or other studies requested by regulatory agencies;

 

·

the duration of patient follow-up; and

 

·

the safety and efficacy profile of the drug candidate.

 

In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate’s commercial potential.

 

General and Administrative

 

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities.

 

Other Income

 

Other income consists of interest income earned on our cash and cash equivalents.

 

21


 

Results of Operations for the Three and Nine Months Ended September 30, 2016 and 2015

 

The following tables set forth our results of operations for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

Revenue

    

$

18

    

$

 —

    

$

18

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

5,921

 

 

5,038

 

 

883

 

General and administrative expense

 

 

1,984

 

 

2,133

 

 

(149)

 

Total costs and expenses

 

 

7,905

 

 

7,171

 

 

734

 

Loss from operations

 

 

(7,887)

 

 

(7,171)

 

 

(716)

 

Other income

 

 

32

 

 

3

 

 

29

 

Net loss and comprehensive loss

 

$

(7,855)

 

$

(7,168)

 

$

(687)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended  September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

Revenue

    

$

18

    

$

20,035

    

$

(20,017)

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

17,221

 

 

18,089

 

 

(868)

 

General and administrative expense

 

 

6,352

 

 

5,844

 

 

508

 

Total costs and expenses

 

 

23,573

 

 

23,933

 

 

(360)

 

Loss from operations

 

 

(23,555)

 

 

(3,898)

 

 

(19,657)

 

Other income

 

 

74

 

 

10

 

 

64

 

Net loss and comprehensive loss

 

$

(23,481)

 

$

(3,888)

 

$

(19,593)

 

 

Revenue

 

Our revenue for the three and nine months ended September 30, 2016 was not material.  We did not record any revenue during the three months ended September 30, 2015. The revenue recorded in the nine months ended September 30, 2015 was due to the $20.0 million non-refundable milestone payment from Pfizer triggered upon the dosing of the first patient in the Phase 3 clinical trial of rivipansel. There were no milestone or royalty payments due from Pfizer during the three and nine months ended September 30, 2016.

 

Research and Development Expense

 

The following tables summarize our research and development expense by functional area for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

Clinical development

    

$

2,389

    

$

629

    

$

1,760

 

Manufacturing and formulation

 

 

893

 

 

1,806

 

 

(913)

 

Contract research services, consulting and other costs

 

 

332

 

 

583

 

 

(251)

 

Laboratory costs

 

 

466

 

 

439

 

 

27

 

Personnel-related

 

 

1,580

 

 

1,372

 

 

208

 

Stock-based compensation

 

 

261

 

 

209

 

 

52

 

Research and development expense

 

$

5,921

 

$

5,038

 

$

883

 

 

 

22


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended  September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

   

Clinical development

    

$

5,403

    

$

1,965

    

$

3,438

 

Manufacturing and formulation

 

 

3,780

 

 

6,436

 

 

(2,656)

 

Contract research services, consulting and other costs

 

 

1,354

 

 

1,834

 

 

(480)

 

Laboratory costs

 

 

1,237

 

 

1,098

 

 

139

 

Personnel-related

 

 

4,675

 

 

4,163

 

 

512

 

Stock-based compensation

 

 

772

 

 

591

 

 

181

 

Milestone license fees

 

 

 —

 

 

2,002

 

 

(2,002)

 

Research and development expense

 

$

17,221

 

$

18,089

 

$

(868)

 

 

During the three months ended September 30, 2016, our research and development expense increased by $883,000, or 18%, compared to the same period in 2015. The increase was due to an increase in the costs associated with the clinical trials for GMI-1271 in AML and MM and for GMI-1359 in healthy volunteers, partially offset by a decrease in expenses related to manufacturing and process development for GMI-1271.

 

During the nine months ended September 30, 2016, our research and development expense decreased by $868,000, or 5%, compared to the same period in 2015. The decrease was primarily due to the milestone license fees of $2.0 million during the nine months ended September 30, 2015 that did not recur in 2016. As part of the original consideration for entering into the agreement with the University, we granted to the University the right to receive 10% of payments related to rivipansel under specified circumstances, including any future milestone payments or royalties we receive from Pfizer.  The payment of milestone license fees reflected in research and development expenses during the nine months ended September 30, 2015 was based on 10% of the associated non-refundable milestone payments of $20 million due from Pfizer to us.  In contrast, because there were no milestone or royalties received from Pfizer in the nine months ended September 30, 2016, we did not incur the associated research and development expense of milestone license fees payable to the University. In addition, during the nine months ended September 30, 2016, as compared to the same period in 2015, there was an increase in the costs associated with the clinical trials for GMI-1271 in AML and MM and for GMI-1359 in healthy volunteers, partially offset by a decrease in expenses related to manufacturing and process development for GMI-1271.

 

The following table summarizes our research and development expense by drug candidate for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

GMI-1271

    

$

2,799

    

$

1,634

    

$

1,165

 

GMI-1359

 

 

715

 

 

1,128

 

 

(413)

 

Rivipansel

 

 

3

 

 

3

 

 

 —

 

Other research and development

 

 

562

 

 

691

 

 

(129)

 

Personnel-related and stock-based compensation

 

 

1,842

 

 

1,582

 

 

260

 

Research and development expense

 

$

5,921

 

$

5,038

 

$

883

 

 

23


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended  September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

GMI-1271

    

$

7,619

    

$

7,499

    

$

120

 

GMI-1359

 

 

2,316

 

 

1,745

 

 

571

 

Rivipansel

 

 

6

 

 

2,017

 

 

(2,011)

 

Other research and development

 

 

1,832

 

 

2,075

 

 

(243)

 

Personnel-related and stock-based compensation

 

 

5,448

 

 

4,753

 

 

695

 

Research and development expense

 

$

17,221

 

$

18,089

 

$

(868)

 

 

General and Administrative Expense

 

The following tables summarizes the components of our general and administrative expense for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended  September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

Personnel-related

    

$

640

    

$

571

    

$

69

 

Stock-based compensation

 

 

479

 

 

424

 

 

55

 

Legal, consulting and other professional expenses

 

 

719

 

 

968

 

 

(249)

 

Other

 

 

146

 

 

170

 

 

(24)

 

General and administrative expense

 

$

1,984

 

$

2,133

 

$

(149)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended  September 30, 

 

Period-to-Period

 

(in thousands)

 

2016

 

2015

 

Change

 

Personnel-related

    

$

2,019

    

$

1,756

    

$

263

 

Stock-based compensation

 

 

1,467

 

 

1,088

 

 

379

 

Legal, consulting and other professional expenses

 

 

2,412

 

 

2,575

 

 

(163)

 

Other

 

 

454

 

 

425

 

 

29

 

General and administrative expense

 

$

6,352

 

$

5,844

 

$

508

 

 

During the three months ended September 30, 2016, our general and administrative expense decreased by $149,000, or 7%, compared to the same period in 2015.  The decrease was related to lower legal expenses, patent fees and commercial research fees. During the nine months ended September 30, 2016, our general and administrative expense increased by $508,000, or 9%, compared to the same period in 2015. The increase was primarily attributable to personnel-related expenses and stock-based compensation expense due to a minor headcount increase in 2016 and stock option and RSU awards granted in the first quarter of 2016.

 

Liquidity and Capital Resources

 

Sources of Liquidity

 

We have financed our operations primarily through private placements of our capital stock, our IPO, our at-the-market offering, our public offering in June 2016 and upfront and milestone payments from Pfizer. As of September 30, 2016, we had $45.3 million in cash and cash equivalents.

 

We are potentially eligible to earn a significant amount of milestone payments and royalties under our agreement with Pfizer. Our ability to earn these payments and their timing is dependent upon the outcome of Pfizer’s activities and is uncertain at this time.

24


 

 

On March 1, 2016, we entered into an at-the-market sales agreement with Cowen, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $40 million through Cowen acting as our sales agent. Also on March 1, 2016, we filed a prospectus supplement offering up to $19 million of shares of our common stock in accordance with the sales agreement.  On June 2, 2016, we filed an amendment to the prospectus supplement to increase the offering to up to a total of $40 million of shares of our common stock, including the shares of common stock that had already been sold in accordance with the sales agreement.  As of September 30, 2016, we have sold an aggregate of 483,298 shares of our common stock under the at-the-market facility, for net proceeds of $2.7 million. Subsequent to September 30, 2016, we sold an additional 1,701 shares under the facility for an additional $12,000 in net proceeds.

 

In June 2016, we completed a public offering in which we sold 3,476,793 shares of common stock at a price of $6.10 per share.  We received net proceeds of $19.7 million from this offering, after deducting underwriting discounts and commissions and other offering expenses.

 

Funding Requirements

 

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.

 

The successful development of any of our drug candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of GMI-1271 or our other drug candidates. We are also unable to predict when, if ever, material net cash inflows will commence from rivipansel or GMI-1271. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

 

·

successful enrollment in, and completion of, clinical trials;

 

·

receipt of marketing approvals from applicable regulatory authorities;

 

·

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

 

·

obtaining and maintaining patent and trade secret protection and regulatory exclusivity for drug candidates; and

 

·

launching commercial sales of drugs, if and when approved, whether alone or in collaboration with others.

 

A change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs and timing associated with the development of that drug candidate. Because our drug candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our drug candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements, including our existing collaboration with Pfizer. Except for Pfizer’s obligation to make milestone payments under our agreement with them, we will not have any committed external source of liquidity.

 

To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of convertible debt securities, these securities could contain covenants that would restrict our operations.

 

We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements in the future, we

25


 

may have to relinquish valuable rights to our drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.

 

Outlook

 

Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our existing cash and cash equivalents as of September 30, 2016 will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2018. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain.

 

Cash Flows

 

The following is a summary of our cash flows for the nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended  September 30, 

 

(in thousands) 

 

2016

 

2015

 

Net cash provided by (used in):

    

 

 

    

 

 

 

Operating activities

 

$

(23,777)

 

$

(1,284)

 

Investing activities

 

 

(266)

 

 

(265)

 

Financing activities

 

 

22,522

 

 

111

 

Net change in cash and cash equivalents

 

$

(1,521)

 

$

(1,439)

 

 

Operating Activities

 

Net cash used in operating activities for the nine months ended September 30, 2016 includes the costs associated with the advancement of the GMI-1271 and GMI-1359 development programs, including the initiation of clinical trials for both product candidates. In addition, the $2.0 million milestone license fee due to the University of Basel and accrued as a liability as of December 31, 2015 was paid during this period. Net cash used in operating activities for the nine months ended September 30, 2015 includes the costs associated with the advancement of the GMI-1271 development program, including the manufacturing supplies and clinical expenses for the initiation of the Phase 1/2 clinical trial, partially offset by $20.0 million in accounts receivable, which relates to the Pfizer milestone payment recorded as revenue in June 2015. In addition, the $1.5 million milestone license fee due to the University of Basel and accrued as a liability as of December 31, 2014 was paid during the nine months ended September 30, 2015. 

 

Investing Activities

 

Net cash used in investing activities for the nine months ended September 30, 2016 included capital expenses relating to the additional leasehold improvements including architect and project management fees. Net cash used in investing activities for the nine months ended September 30, 2015 included capital expenses related to moving into our new headquarters in June 2015, including the acquisition of new furniture, fixtures and lab equipment.

 

Financing Activities

 

Net cash provided by financing activities during the nine months ended September 30, 2016 is primarily comprised of the net proceeds of $19.7 million from our June 2016 public offering and $2.7 million from at-the-market sales under our sales agreement with Cowen. Net cash provided by financing activities during the nine months ended September 30, 2015 reflects the receipt of cash upon the exercise of stock options.

26


 

Contractual Obligations

As of September 30, 2016, our significant contractual obligations consisted solely of rent obligations under a non-cancelable lease, as amended, for our current office space in Rockville, Maryland, which has a term through October 2023.

The following table depicts our remaining rent obligations under this lease as of September 30, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Payments Due by Period 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

After

 

 

 

Total 

 

2016

   

2017

 

2018

 

2019

 

2020

 

2020

 

 

 

(In thousands)

 

Operating lease

    

$

7,156

    

$

233

    

$

942

    

$

965

    

$

990

    

$

1,014

    

$

3,012

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The foregoing table does not include various agreements that we have entered into for services with third-party vendors, including agreements to conduct clinical trials, to manufacture products, and for consulting and other contracted services due to the cancelable nature of the services. We accrue the costs of these agreements based on estimates of work completed to date.

The contractual obligations table does not include any potential future payments we may be required to make under our research agreement with the University of Basel, under which we have agreed to pay 10% of any future milestone payments or royalties we may receive from Pfizer with respect to rivipansel. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be paid by us cannot be determined as of the date of this report.

 

Off-Balance Sheet Arrangements

 

During the nine months ended September 30, 2016, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

 

JOBS Act

 

In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of September 30, 2016 and December 31, 2015, we had cash and cash equivalents of $45.3 million and $46.8 million, respectively. We generally hold our cash in interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.

 

 

Item 4. Controls and Procedures

 

(a) Evaluation of Disclosure Controls and Procedures

 

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, refers to controls and procedures that are designed to ensure

27


 

that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Security and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2016, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of such date at the reasonable assurance level.

 

(b) Changes in Internal Controls Over Financial Reporting

 

There have not been any changes in our internal controls over financial reporting during our fiscal quarter ended September 30, 2016 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we are subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

 

Item 1A. Risk Factors

 

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Our risk factors as of the date of this quarterly report on Form 10-Q have not changed materially from those described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on February 29, 2016.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

In July 2016, we issued 22,367 shares of common stock to an existing stockholder upon the net exercise of a warrant.  The issuance of these securities was exempt from registration under Section 3(a)(9) of the Securities Act.

 

28


 

Item 6. Exhibits

 

 

 

 

Exhibit
No.

 

Document

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on January 15, 2014).

 

 

 

3.2

 

Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on January 15, 2014).

 

 

 

4.1

 

Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to Exhibit 4.2 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-191567), filed with the Commission on October 31, 2013).

 

 

 

31.1*

 

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

 

 

 

31.2*

 

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

 

 

 

32.1**

 

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document


*     Filed herewith

 

**   These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

29


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

GLYCOMIMETICS, INC.

 

 

 

 

Date: November 4, 2016

 

By:

/s/ Brian M. Hahn

 

 

 

Brian M. Hahn

 

 

 

Chief Financial Officer

 

 

 

(On behalf of the Registrant and as Principal Financial Officer)

 

 

30


 

Exhibit Index

 

 

 

 

Exhibit
No.

 

Document

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on January 15, 2014).

 

 

 

3.2

 

Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36177), filed with the Commission on January 15, 2014).

 

 

 

4.1

 

Specimen stock certificate evidencing shares of Common Stock (incorporated herein by reference to Exhibit 4.2 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-191567), filed with the Commission on October 31, 2013).

 

 

 

31.1*

 

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

 

 

 

31.2*

 

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

 

 

 

32.1**

 

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document


*     Filed herewith

 

**   These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

31


EX-31.1 2 glyc-20160930ex311fdfe11.htm EX-31.1 glyc_Ex31_1

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rachel K. King, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2016 of GlycoMimetics, Inc. (the “registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2016

 

 

 

 

 

 

/s/ Rachel K. King

 

 

Rachel K. King

 

 

Chief Executive Officer

 

 

(principal executive officer)

 


EX-31.2 3 glyc-20160930ex312460a7f.htm EX-31.2 glyc_Ex31_2

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Brian M. Hahn, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2016 of GlycoMimetics, Inc. (the “registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2016

 

 

 

 

 

 

/s/ Brian M. Hahn

 

 

Brian M. Hahn

 

 

Chief Financial Officer

 

 

(principal financial officer)

 


EX-32.1 4 glyc-20160930ex3217de671.htm EX-32.1 glyc_Ex32_1

Exhibit 32.1

 

CERTIFICATIONS OF

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Rachel K. King, Chief Executive Officer of GlycoMimetics, Inc. (the “Company”), and Brian M. Hahn, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

 

1.

The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2016, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

 

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 4th day of November,  2016. 

 

 

 

 

/s/ Rachel K. King

 

/s/ Brian M. Hahn

Rachel K. King

 

Brian M. Hahn

Chief Executive Officer

 

Chief Financial Officer


*This certification accompanies the Periodic Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of GlycoMimetics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Periodic Report), irrespective of any general incorporation language contained in such filing.


EX-101.INS 5 glyc-20160930.xml EX-101.INS 0001253689 us-gaap:CommonStockMember glyc:AtMarketOfferingMember 2016-09-30 0001253689 us-gaap:CommonStockMember glyc:PublicEquityOfferingMember 2016-06-30 0001253689 glyc:StockIncentivePlan2003Member 2015-01-01 2015-12-31 0001253689 glyc:StockIncentivePlan2003Member 2015-12-31 0001253689 glyc:EquityIncentivePlan2013Member 2015-12-31 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:CommonStockMember 2016-01-01 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:CommonStockMember 2016-01-01 2016-01-01 0001253689 glyc:EquityIncentivePlan2013Member 2015-01-01 2015-09-30 0001253689 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001253689 us-gaap:RestrictedStockUnitsRSUMember glyc:EquityIncentivePlan2013Member 2015-12-31 0001253689 glyc:StockIncentivePlan2003Member us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-01-01 2016-09-30 0001253689 glyc:StockIncentivePlan2003Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-01-01 2016-09-30 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2014-01-09 2014-01-09 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2014-01-09 2014-01-09 0001253689 glyc:RockvilleMember 2016-05-31 0001253689 us-gaap:CommonStockMember glyc:PublicEquityOfferingMember 2016-06-01 2016-06-30 0001253689 us-gaap:CommonStockMember glyc:AtMarketOfferingMember 2016-03-01 2016-09-30 0001253689 glyc:PfizerMember glyc:AchievementOfSpecifiedDevelopmentMilestoneMember glyc:LicenseAgreementMember 2015-06-01 2015-06-30 0001253689 glyc:PfizerMember glyc:AchievementOfSpecifiedDevelopmentMilestoneMember glyc:LicenseAgreementMember 2014-05-01 2014-05-31 0001253689 us-gaap:OfficeEquipmentMember 2016-09-30 0001253689 us-gaap:LeaseholdImprovementsMember 2016-09-30 0001253689 us-gaap:FurnitureAndFixturesMember 2016-09-30 0001253689 us-gaap:ConstructionInProgressMember 2016-09-30 0001253689 us-gaap:ComputerEquipmentMember 2016-09-30 0001253689 glyc:LaboratoryEquipmentMember 2016-09-30 0001253689 us-gaap:OfficeEquipmentMember 2015-12-31 0001253689 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001253689 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001253689 us-gaap:ComputerEquipmentMember 2015-12-31 0001253689 glyc:LaboratoryEquipmentMember 2015-12-31 0001253689 glyc:StockIncentivePlan2003Member 2015-01-01 2015-09-30 0001253689 us-gaap:FairValueInputsLevel1Member 2016-09-30 0001253689 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001253689 glyc:StockIncentivePlan2003Member 2016-09-30 0001253689 glyc:EquityIncentivePlan2013Member 2016-09-30 0001253689 us-gaap:RestrictedStockUnitsRSUMember glyc:EquityIncentivePlan2013Member 2016-09-30 0001253689 glyc:EquityIncentivePlan2013Member 2016-01-01 2016-09-30 0001253689 glyc:PfizerMember us-gaap:UpFrontPaymentArrangementMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 2015-09-30 0001253689 2014-12-31 0001253689 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001253689 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001253689 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001253689 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001253689 us-gaap:WarrantMember 2016-07-01 2016-09-30 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2016-07-01 2016-09-30 0001253689 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2016-01-01 2016-09-30 0001253689 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2015-07-01 2015-09-30 0001253689 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001253689 glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember 2015-01-01 2015-09-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001253689 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001253689 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001253689 glyc:PfizerMember us-gaap:UpFrontPaymentArrangementMember glyc:LicenseAgreementMember 2011-10-01 2013-03-31 0001253689 glyc:StockIncentivePlan2003Member 2016-01-01 2016-09-30 0001253689 glyc:EquityIncentivePlan2013Member 2014-01-09 2014-01-09 0001253689 us-gaap:RestrictedStockUnitsRSUMember glyc:EquityIncentivePlan2013Member 2016-01-01 2016-09-30 0001253689 glyc:UniversityOfBaselMember glyc:ResearchServicesAgreementMember 2016-01-01 2016-09-30 0001253689 glyc:UniversityOfBaselMember glyc:ResearchServicesAgreementMember 2016-02-01 2016-02-29 0001253689 glyc:PfizerMember us-gaap:MaximumMember glyc:AchievementOfSpecifiedRegulatoryMilestoneMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 glyc:PfizerMember us-gaap:MaximumMember glyc:AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 glyc:PfizerMember us-gaap:MaximumMember glyc:AchievementOfSpecifiedDevelopmentMilestoneMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:CommonStockMember 2015-12-31 0001253689 glyc:EquityIncentivePlan2013Member us-gaap:CommonStockMember 2014-01-09 0001253689 glyc:PfizerMember glyc:AchievementOfSpecifiedRegulatoryMilestoneMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 glyc:PfizerMember glyc:AchievementOfSpecifiedDevelopmentMilestoneMember glyc:LicenseAgreementMember 2011-10-01 2011-10-31 0001253689 2015-01-01 2015-09-30 0001253689 2016-07-01 2016-09-30 0001253689 2015-07-01 2015-09-30 0001253689 2016-09-30 0001253689 glyc:UniversityOfBaselMember glyc:ResearchServicesAgreementMember 2015-12-31 0001253689 2015-12-31 0001253689 2016-11-03 0001253689 2016-01-01 2016-09-30 iso4217:USD xbrli:shares glyc:installment xbrli:pure glyc:item iso4217:USD xbrli:shares false --12-31 Q3 2016 2016-09-30 10-Q 0001253689 23065131 Yes Accelerated Filer GLYCOMIMETICS INC 3590 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Accrued Liabilities </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&nbsp;analyses of data that justify the progress; and (iv)&nbsp;the Company&#x2019;s judgment.</font> </p><div /></div> </div> 2000000 2000000 3423220 2323255 0 0 0 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">7. Stockholders&#x2019; Equity </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">At-The-Market Equity Offering</font> </p> <p style="margin:0pt;font-family:Calibri;font-size: 11pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company&#x2019;s securities under a shelf registration statement filed in March 2015. As of September 30, 2016, the Company had issued and sold 483,298 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.296, for aggregate net proceeds of $2.7 million, after deducting commissions and offering expenses.</font> </p> <p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;"> Equity Offering</font> </p> <p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;color:#000000;">In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share.&nbsp;The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">2003 Stock Incentive Plan </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60&nbsp;days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&nbsp;21, 2013. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2003 Plan for the nine months ended September 30, 2016 is as follows: </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>758,187 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.27 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options exercised</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,268) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.49 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options forfeited</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>730,919 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,306 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested or expected to vest as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>730,888 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,306 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercisable as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,565 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,301 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27.35pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of September 30, 2016, there was $2,991 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over a weighted-average period less than one year. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 and 2015 was $95,221 and $699,196, respectively, and total cash received for options exercised was $40,668 and $110,697 during the nine months ended September 30, 2016 and 2015, respectively. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $14,450 and $38,223, respectively. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">2013 Equity Incentive Plan </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code to the Company&#x2019;s employees and its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90&nbsp;days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Authorized Shares </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The maximum number of shares of common stock that initially could be issued under the 2013 Plan was &nbsp; &nbsp;1,000,000&nbsp;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan automatically increases on January&nbsp;1 of each year until January&nbsp;1, 2023, by 3% of the total number of shares of common stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January&nbsp;1, 2016, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 571,506 shares, representing 3% of the total number of shares of common stock outstanding on December 31, 2015, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,139,701 shares. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the nine months ended September 30, 2016 is as follows: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">ccc</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,470,338 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options granted</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>618,250 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.35 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options exercised</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,500) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.95 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options forfeited</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,591) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.20 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,062,497 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,110 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested or expected to vest as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,053,321 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,100 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercisable as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>828,814 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.7 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The weighted-average fair value of the options granted during the nine months ended September 30, 2016 and 2015 was $3.38 per share and $5.09 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended </font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected term </font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6.25 years</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6.25 years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68.86% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80.83% </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.70% </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected dividend yield</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:27.35pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of September 30, 2016, there was $5,014,309 of total unrecognized compensation expense related to unvested options under the 2013 Plan that will be recognized over a weighted-average period of approximately 2.2 years. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 was $2,275 and total cash received for options exercised was $27,825 during the nine months ended September 30, 2016. There were no options exercised during the nine months ending September 30, 2015. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $2,364,683 and $2,314,557, respectively. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of September 30, 2016, there was $70,027 of unrecognized compensation costs related to unvested service RSUs. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following is a summary of RSU activity under the 2013 Plan for the nine months ended September 30, 2016: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">GRANT DATE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OF SHARES</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">FAIR VALUE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,833 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.61 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unvested at September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,333 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.36 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based compensation expense was classified on the statement of operations as follows for the three and nine months ended September 30, 2016 and 2015: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:24.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Research and development expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260,882 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>209,359 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>772,163 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,633 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">General and administrative expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,531 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>423,565 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,466,484 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,088,035 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>739,413 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>632,924 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,238,647 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,678,668 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Warrants to Acquire Common Stock</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">During the three months ended September 30, 2016, &nbsp;22,367 shares of common stock were issued to an existing stockholder upon the net exercise of a warrant. &nbsp;No warrants were exercised during the three months ended September 30, 2015.&nbsp; No warrants expired during the three months ended September 30, 2016 and 2015. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 89514 679177 63000 2 2 0.03 0.03 115000000 135000000 70000000 -2000000 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">9. Research and License Agreements</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In October 2011, the Company and Pfizer entered into the Pfizer Agreement that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 clinical trial, after which Pfizer assumed all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Agreement by giving prior written notice. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-front payment was recognized over a period of 1.5 years. In May 2014, Pfizer made a $15.0 million non-refundable milestone payment to the Company, which was recognized as revenue by the Company in May 2014 when earned.&nbsp;&nbsp;In June 2015, Pfizer dosed the first patient in the Phase 3 clinical trial of rivipansel, which triggered a non-refundable milestone payment to the Company of $20.0 million, which the Company recognized as revenue in June 2015.</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe to the University 10% of all future milestone and royalty payments received from Pfizer with respect to rivipansel.&nbsp;&nbsp;As of December&nbsp;31, 2015, a $2.0 million milestone license fee was recorded as an accrued liability representing 10% of the $20.0 million non-refundable milestone payment that the Company received from Pfizer in 2015.&nbsp;&nbsp;The accrued liability of $2.0 million was paid in February 2016. </font> </p><div /></div> </div> 0.10 3 P90D P60D 20000000 22367 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Unaudited Financial Statements </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The accompanying balance sheet as of September 30, 2016 and statements of operations and comprehensive loss for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&nbsp;31, 2015 contained in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 29, 2016. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015. The December&nbsp;31, 2015 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2016 and 2015 are unaudited. Interim results are not necessarily indicative of results for an entire year. </font> </p><div /></div> </div> P1Y6M <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">5. Accrued Expenses</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following is a summary of the Company&#x2019;s accrued expenses: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued research and development expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,255 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,220 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued license and milestone fees</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000,000 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued consulting and other professional fees</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263,211 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242,227 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Other accrued expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>327,018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,152 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued employee benefits</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>349,875 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,442 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued franchise and other taxes</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,590 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,263,359 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 564235 1246739 1037112 826455 195442 349875 6145631 3263359 242227 263211 902099 1036283 127619078 152375985 1678668 1088035 590633 632924 423565 209359 2238647 1466484 772163 739413 478531 260882 2250008 590595 2250008 590595 2815166 555412 2815166 555412 48462279 48010710 47244370 46522266 0 0 0 0 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Basis of Accounting </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). </font> </p><div /></div> </div> 29329 55198923 53759839 46802560 45282550 -1439084 -1520010 0.001 0.001 100000000 100000000 19050204 23063430 19050204 23063430 19049 23062 <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Comprehensive Loss</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and nine months ended September 30, 2016 and 2015, the Company&#x2019;s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of money market funds with major financial institutions in the United States. These funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. </font> </p><div /></div> </div> 0 0 <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following is a summary of the Company&#x2019;s prepaid expenses and other current assets: </font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667,644 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>393,857 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Other receivables</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>572,072 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,683 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Deposits</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses and other current assets</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,239,716 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 243647 922824 81398 243647 841426 22500000 22500000 9270 142417 51882 139749 45808 -0.20 -0.38 -1.14 -0.34 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Net Loss Per Common Share </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock options, restricted stock units and warrants.</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share is computed as follows: </font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,481,241) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,887,795) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,049,347 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,025,623 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,638,129 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,999,705 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Warrants</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock options and restricted stock units</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> P2Y2M12D P1Y 70027 5014309 2991 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company had no&nbsp;assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of September 30, 2016 and December&nbsp;31, 2015. The carrying value of cash held in money market funds of approximately $44.1&nbsp;million and $45.5 million as of September 30, 2016 and December&nbsp;31, 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). </font> </p><div /></div> </div> -8001 5843680 2132993 6352355 1983795 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">8. Income Taxes</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has not recorded any tax provision or benefit for the nine months ended September 30, 2016 and 2015. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at September 30, 2016 and December&nbsp;31, 2015. </font> </p><div /></div> </div> -240935 682504 727701 -3122258 -52320 -198015 797906 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">6. Operating Leases</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease. </font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance</font><font style="display:inline;color:#000000;"> reflected in the Company&#x2019;s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, </font><font style="display:inline;">the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&#x2019;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#x2019;s renewal option set forth in the Lease. The Company&#x2019;s one-time option to terminate the Lease effective as of October 31, 2020 also applies to the additional space. </font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Deferred rent related to the Lease was $922,824 and $243,647 at September 30, 2016 and December 31, 2015, respectively. Total rent expense under the Company&#x2019;s operating leases was $219,983 and $216,765 for the three months ended September 30, 2016 and 2015, respectively, and $557,262 and $437,125 for the nine months ended September 30, 2016 and 2015, respectively.</font> </p> <p style="margin:0pt;text-indent:27pt;text-align:justify;text-justify:inter-ideograph;vertical-align:top;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 7990625 6259377 48462279 48010710 7746978 5417951 0 0 0 0 45500000 44100000 <div> <div> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Notes to Unaudited Financial Statement<a name="NotestoUnauditedFinancialStatements_6637"></a>s</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">1. Description of the Business</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April&nbsp;4, 2003 and commenced operations on May&nbsp;21, 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates or commenced commercial operations. The Company is subject to a number of risks similar to those of other companies in similar development stages, including dependence on key individuals, the need to develop commercially viable drugs, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its drug candidates. The Company has incurred significant operating losses since inception and has relied on its ability to fund its operations through private and public equity financings, and management expects operating losses and negative operating cash flows to continue for the foreseeable future.&nbsp;As the Company continues to incur losses, profitability will be dependent upon the successful development, approval, and commercialization of its drug candidates and achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&nbsp;The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital.&nbsp;Management intends to fund future operations through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources. &nbsp;</font> </p><div /></div> </div> 110697 22522273 -265367 -265635 -1284414 -23776648 -3887795 -7168071 -23481241 -7854693 23932674 7171373 23573715 7905256 -3897299 -7171373 -23555215 -7886756 437125 216765 557262 219983 281152 327018 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">3. Prepaid Expenses and Other Current Assets</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following is a summary of the Company&#x2019;s prepaid expenses and other current assets: </font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>667,644 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>393,857 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Other receivables</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>572,072 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,683 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Deposits</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses and other current assets</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,239,716 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 9504 3302 73974 32063 38683 572072 265367 265635 0.001 0.001 5000000 5000000 0 0 0 0 441810 1239716 393857 667644 696531 759531 110697 68488 110697 27825 40668 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">4. Property and Equipment </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment, net consists of the following: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>978,511 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,586 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Office equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,172 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,053 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Construction in progress</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271,355 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,876 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,423,477 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Less accumulated depreciation</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,036,283) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(902,099) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment, net</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>676,593 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Depreciation expense was $45,808 and $51,882 for the three months ended September 30, 2016 and 2015, respectively, and $139,749 and $142,417 for the nine months ended September 30, 2016 and 2015, respectively.</font> </p><div /></div> </div> 1423477 965586 181053 230987 36128 9723 1712876 978511 186172 271355 230987 36128 9723 521378 676593 <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment, net consists of the following: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Furniture and fixtures</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Laboratory equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>978,511 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,586 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Office equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>186,172 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,053 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Construction in progress</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>271,355 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,712,876 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,423,477 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Less accumulated depreciation</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,036,283) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 3.6pt 0.05pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:10.35pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(902,099) </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:10.35pt;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Property and equipment, net</font></p> </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>676,593 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0.05pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 18088994 5038380 17221360 5921461 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Costs </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.</font> </p><div /></div> </div> -87166473 -110647714 15000000 20000000 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Revenue Recognition </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has entered into a collaborative research and development agreement with Pfizer Inc. (Pfizer). The agreement is in the form of a license agreement (the Pfizer Agreement). The Pfizer Agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The Pfizer Agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the Pfizer Agreement that contain material financial consequences to the Company. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The primary deliverable under this arrangement is an exclusive worldwide license to the Company&#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&#x2019;s behalf. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of Accounting Standards Codification (ASC) 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&nbsp;an estimated selling price, if neither VSOE nor TPE is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering into such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer Agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC 605-25, each required deliverable under the Pfizer Agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&#x2019;s technology and the related proprietary nature of the Company&#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the Pfizer Agreement and will be combined with the research and development services (including participation on a joint steering committee). </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As such, the $22.5 million up-front payment received was recognized as revenue over the expected development period through March 2013. The determination of the length of the period over which to defer revenue and the methodology by which to recognize the related revenues is subject to judgment and estimation. Consistent with the research plan developed by and agreed to by both parties, management estimated that the research activities and participation on the joint steering committees would occur over a 1.5-year period. Revenues associated with the up-front license fee were recognized over this period using a straight-line method, which was consistent with expected completion of the research services. The research services were completed in March 2013, consistent with the expected development period. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC 605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Milestone Method</font><font style="display:inline;">, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#x2019;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment.</font> </p><div /></div> </div> 20035375 18500 18500 22453785 2700000 19700000 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued research and development expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,255 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,220 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued license and milestone fees</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000,000 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued consulting and other professional fees</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>263,211 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242,227 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Other accrued expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>327,018 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,152 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued employee benefits</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>349,875 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,442 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued franchise and other taxes</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,590 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:71.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued expenses</font></p> </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,263,359 </td> <td valign="bottom" style="width:02.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:09.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Warrants</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock options and restricted stock units</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share is computed as follows: </font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,481,241) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,887,795) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,049,347 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,025,623 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,638,129 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,999,705 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based compensation expense was classified on the statement of operations as follows for the three and nine months ended September 30, 2016 and 2015: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:24.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Calibri;">&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Research and development expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260,882 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>209,359 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>772,163 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,633 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">General and administrative expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,531 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>423,565 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,466,484 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,088,035 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total stock-based compensation expense</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>739,413 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>632,924 </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,238,647 </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,678,668 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following is a summary of RSU activity under the 2013 Plan for the nine months ended September 30, 2016: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">GRANT DATE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OF SHARES</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">FAIR VALUE</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,833 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.61 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unvested at September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,333 </td> <td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.36 </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the nine months ended September 30, 2016 is as follows: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">ccc</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,470,338 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options granted</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>618,250 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.35 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options exercised</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,500) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.95 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options forfeited</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(22,591) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.20 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,062,497 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,110 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested or expected to vest as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,053,321 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,100 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:33.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercisable as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:00.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>828,814 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.7 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2003 Plan for the nine months ended September 30, 2016 is as follows: </font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>758,187 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.27 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options exercised</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,268) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.49 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options forfeited</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Outstanding as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>730,919 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,306 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vested or expected to vest as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>730,888 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,306 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercisable as of September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,565 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.5 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,301 </td> <td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended </font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;2016</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected term </font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6.25 years</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">6.25 years</font></p> </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected volatility</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68.86% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80.83% </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Risk-free interest rate</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.69% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.70% </td> </tr> <tr> <td valign="bottom" style="width:44.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expected dividend yield</font></p> </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> <td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:24.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0% </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 52320 52320 0.25 0.02083 0.25 0.02083 0 0.00 14500 4.61 4833 19333 7.62 5.36 0 0.00 P10Y P10Y P10Y 0.0000 0.0000 P6Y3M P6Y3M P6Y3M 0.8083 0.6886 0.0170 0.0169 571506 1000000 2139701 1000 4301000 828814 729565 8.26 1.25 P7Y8M12D P3Y6M 699196 2275 95221 22591 618250 5.09 3.38 1110000 4306000 1470338 758187 2062497 730919 8.26 1.27 7.41 1.26 P4Y2M12D P3Y6M 1100000 4306000 2053321 730888 7.41 1.26 P8Y2M12D P3Y6M 2314557 38223 2364683 14450 7.95 1.49 6.20 5.35 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&#x2014;Stock Compensation</font><font style="display:inline;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Volatility</font><font style="display:inline;">&#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&#x2019;s initial public offering, there was not a market for the Company&#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering, to determine its expected volatility. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Term</font><font style="display:inline;">&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Forfeiture Rate</font><font style="display:inline;">&#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Equity instruments issued to nonemployees are accounted for under the provisions of ASC 718,</font><font style="display:inline;font-style:italic;"> Compensation&#x2014;Stock Compensation</font><font style="display:inline;">, and ASC 505-50, </font><font style="display:inline;font-style:italic;">Equity&#x2014;Equity-Based Payments to Non-Employees</font><font style="display:inline;">. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services are completed and are marked to market during the service period.</font> </p><div /></div> </div> 6.10 6.296 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">2. Significant Accounting Policies</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Basis of Accounting </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Unaudited Financial Statements </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The accompanying balance sheet as of September 30, 2016 and statements of operations and comprehensive loss for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December&nbsp;31, 2015 contained in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 29, 2016. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015. The December&nbsp;31, 2015 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2016 and 2015 are unaudited. Interim results are not necessarily indicative of results for an entire year. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company had no&nbsp;assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of September 30, 2016 and December&nbsp;31, 2015. The carrying value of cash held in money market funds of approximately $44.1&nbsp;million and $45.5 million as of September 30, 2016 and December&nbsp;31, 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of money market funds with major financial institutions in the United States. These funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Revenue Recognition </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has entered into a collaborative research and development agreement with Pfizer Inc. (Pfizer). The agreement is in the form of a license agreement (the Pfizer Agreement). The Pfizer Agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The Pfizer Agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the Pfizer Agreement that contain material financial consequences to the Company. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The primary deliverable under this arrangement is an exclusive worldwide license to the Company&#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&#x2019;s behalf. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of Accounting Standards Codification (ASC) 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&nbsp;an estimated selling price, if neither VSOE nor TPE is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering into such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer Agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC 605-25, each required deliverable under the Pfizer Agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&#x2019;s technology and the related proprietary nature of the Company&#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the Pfizer Agreement and will be combined with the research and development services (including participation on a joint steering committee). </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As such, the $22.5 million up-front payment received was recognized as revenue over the expected development period through March 2013. The determination of the length of the period over which to defer revenue and the methodology by which to recognize the related revenues is subject to judgment and estimation. Consistent with the research plan developed by and agreed to by both parties, management estimated that the research activities and participation on the joint steering committees would occur over a 1.5-year period. Revenues associated with the up-front license fee were recognized over this period using a straight-line method, which was consistent with expected completion of the research services. The research services were completed in March 2013, consistent with the expected development period. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC 605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Milestone Method</font><font style="display:inline;">, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#x2019;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. &nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Accrued Liabilities </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&nbsp;analyses of data that justify the progress; and (iv)&nbsp;the Company&#x2019;s judgment.&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Costs </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&#x2014;Stock Compensation</font><font style="display:inline;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Volatility</font><font style="display:inline;">&#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&#x2019;s initial public offering, there was not a market for the Company&#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering, to determine its expected volatility. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Term</font><font style="display:inline;">&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-style:italic;">Expected Forfeiture Rate</font><font style="display:inline;">&#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted. </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Equity instruments issued to nonemployees are accounted for under the provisions of ASC 718,</font><font style="display:inline;font-style:italic;"> Compensation&#x2014;Stock Compensation</font><font style="display:inline;">, and ASC 505-50, </font><font style="display:inline;font-style:italic;">Equity&#x2014;Equity-Based Payments to Non-Employees</font><font style="display:inline;">. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services are completed and are marked to market during the service period.&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Net Loss Per Common Share </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock options, restricted stock units and warrants.</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share is computed as follows: </font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:25.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:26.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.40pt;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(23,481,241) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,887,795) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted net loss per common share</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14) </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.20) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,049,347 </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,025,623 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,638,129 </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,999,705 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:42.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive: </font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:25.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Warrants</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>555,412 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:43.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock options and restricted stock units</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,815,166 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:12.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,250,008 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Comprehensive Loss</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and nine months ended September 30, 2016 and 2015, the Company&#x2019;s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.&nbsp;&nbsp;</font> </p><div /></div> </div> 40471654 41751333 483298 3476793 0 3500 27268 1678668 2238647 <div> <div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</font> </p><div /></div> </div> 18999705 19025623 20638129 23049347 EX-101.SCH 6 glyc-20160930.xsd EX-101.SCH 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Description of the Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Research and License Agreements link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Significant Accounting Policies - 10-Q (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Stockholders Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - 10-Q (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Operating Leases - 10Q (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Stockholders' Equity - Equity Offerings (Detail) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Stockholders' Equity - Incentive Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 40705 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 40706 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Income Taxes - 10-Q (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Research and License Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 glyc-20160930_cal.xml EX-101.CAL EX-101.DEF 8 glyc-20160930_def.xml EX-101.DEF EX-101.LAB 9 glyc-20160930_lab.xml EX-101.LAB EX-101.PRE 10 glyc-20160930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2016
Nov. 03, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Entity Registrant Name GLYCOMIMETICS INC  
Entity Central Index Key 0001253689  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   23,065,131
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current Assets:    
Cash and cash equivalents $ 45,282,550 $ 46,802,560
Prepaid expenses and other current assets 1,239,716 441,810
Total current assets 46,522,266 47,244,370
Property and equipment, net 676,593 521,378
Deposits 52,320  
Prepaid research and development expenses 759,531 696,531
Total assets 48,010,710 48,462,279
Current liabilities:    
Accounts payable 1,246,739 564,235
Accrued bonuses 826,455 1,037,112
Accrued expenses 3,263,359 6,145,631
Deferred rent 81,398  
Total current liabilities 5,417,951 7,746,978
Deferred rent, net of current portion 841,426 243,647
Total liabilities 6,259,377 7,990,625
Stockholders' equity:    
Preferred Stock; $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2016 and December 31, 2015
Common stock; $0.001 par value; 100,000,000 shares authorized, 23,063,430 shares issued and outstanding at September 30, 2016; 100,000,000 shares authorized, 19,050,204 shares issued and outstanding at December 31, 2015 23,062 19,049
Additional paid-in capital 152,375,985 127,619,078
Accumulated deficit (110,647,714) (87,166,473)
Total stockholders' equity 41,751,333 40,471,654
Total liabilities and stockholders' equity $ 48,010,710 $ 48,462,279
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Balance Sheets    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 23,063,430 19,050,204
Common stock, shares outstanding 23,063,430 19,050,204
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statements of Operations and Comprehensive (Loss) Income        
Revenue $ 18,500   $ 18,500 $ 20,035,375
Costs and expenses:        
Research and development expense 5,921,461 $ 5,038,380 17,221,360 18,088,994
General and administrative expense 1,983,795 2,132,993 6,352,355 5,843,680
Total costs and expenses 7,905,256 7,171,373 23,573,715 23,932,674
Loss from operations (7,886,756) (7,171,373) (23,555,215) (3,897,299)
Other income 32,063 3,302 73,974 9,504
Net loss and comprehensive loss $ (7,854,693) $ (7,168,071) $ (23,481,241) $ (3,887,795)
Basic and diluted net loss per common share (in dollars per share) $ (0.34) $ (0.38) $ (1.14) $ (0.20)
Basic and diluted weighted average number of common shares (in shares) 23,049,347 19,025,623 20,638,129 18,999,705
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating activities    
Net loss $ (23,481,241) $ (3,887,795)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 139,749 142,417
Loss on disposal of property and equipment   8,001
Stock-based compensation expense 2,238,647 1,678,668
Changes in assets and liabilities    
Prepaid expenses and other current assets (797,906) 198,015
Prepaid research and development expenses (63,000)  
Deposits (52,320)  
Accounts payable 682,504 (240,935)
Accrued expenses (3,122,258) 727,701
Deferred rent 679,177 89,514
Net cash used in operating activities (23,776,648) (1,284,414)
Investing activities    
Purchases of property and equipment (265,635) (265,367)
Net cash used in investing activities (265,635) (265,367)
Financing activities    
Proceeds from issuance of common stock, net of issuance costs 22,453,785  
Proceeds from exercise of stock options 68,488 110,697
Net cash provided by financing activities 22,522,273 110,697
Net change in cash and cash equivalents (1,520,010) (1,439,084)
Cash and cash equivalents, beginning of period 46,802,560 55,198,923
Cash and cash equivalents, end of period 45,282,550 $ 53,759,839
Supplemental disclosure of non-cash investing activities:    
Property asset acquisition included in accounts payable and accrued expenses $ 29,329  
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Description of the Business
9 Months Ended
Sep. 30, 2016
Description of the Business  
Description of the Business

GLYCOMIMETICS, INC.

Notes to Unaudited Financial Statements

 

1. Description of the Business

 

GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April 4, 2003 and commenced operations on May 21, 2003. The Company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

 

The Company’s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates or commenced commercial operations. The Company is subject to a number of risks similar to those of other companies in similar development stages, including dependence on key individuals, the need to develop commercially viable drugs, competition from other companies, many of whom are larger and better capitalized, and the need to obtain adequate additional financing to fund the development of its drug candidates. The Company has incurred significant operating losses since inception and has relied on its ability to fund its operations through private and public equity financings, and management expects operating losses and negative operating cash flows to continue for the foreseeable future. As the Company continues to incur losses, profitability will be dependent upon the successful development, approval, and commercialization of its drug candidates and achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. Management intends to fund future operations through additional public or private equity or debt offerings and may seek additional capital through arrangements with strategic partners or from other sources.  

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2016
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Significant Accounting Policies

 

Basis of Accounting

 

The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).

 

Unaudited Financial Statements

 

The accompanying balance sheet as of September 30, 2016 and statements of operations and comprehensive loss for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2015 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 29, 2016. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015. The December 31, 2015 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2016 and 2015 are unaudited. Interim results are not necessarily indicative of results for an entire year.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

 

Fair Value Measurements

 

The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of September 30, 2016 and December 31, 2015. The carrying value of cash held in money market funds of approximately $44.1 million and $45.5 million as of September 30, 2016 and December 31, 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).

 

Concentration of Credit Risk

 

Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of money market funds with major financial institutions in the United States. These funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.

 

Revenue Recognition

 

From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements.

 

The Company has entered into a collaborative research and development agreement with Pfizer Inc. (Pfizer). The agreement is in the form of a license agreement (the Pfizer Agreement). The Pfizer Agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The Pfizer Agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the Pfizer Agreement that contain material financial consequences to the Company.

 

The primary deliverable under this arrangement is an exclusive worldwide license to the Company’s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer’s behalf.

 

Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of Accounting Standards Codification (ASC) 605-25, Revenue Recognition—Multiple-Element Arrangements, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis and (2) if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i) vendor-specific objective evidence (VSOE), if available; (ii) third-party evidence (TPE) of selling price if VSOE is not available; or (iii) an estimated selling price, if neither VSOE nor TPE is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering into such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer Agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company’s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data.

 

Pursuant to ASC 605-25, each required deliverable under the Pfizer Agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company’s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company’s technology and the related proprietary nature of the Company’s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the Pfizer Agreement and will be combined with the research and development services (including participation on a joint steering committee).

 

As such, the $22.5 million up-front payment received was recognized as revenue over the expected development period through March 2013. The determination of the length of the period over which to defer revenue and the methodology by which to recognize the related revenues is subject to judgment and estimation. Consistent with the research plan developed by and agreed to by both parties, management estimated that the research activities and participation on the joint steering committees would occur over a 1.5-year period. Revenues associated with the up-front license fee were recognized over this period using a straight-line method, which was consistent with expected completion of the research services. The research services were completed in March 2013, consistent with the expected development period.

 

Pursuant to ASC 605-28, Revenue Recognition—Milestone Method, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement.

 

Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment.  

 

Accrued Liabilities

 

The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company’s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company’s judgment. 

 

Research and Development Costs

 

Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.

 

Stock-Based Compensation

 

Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.

 

The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.

 

A discussion of management’s methodology for developing some of the assumptions used in the valuation model follows:

 

Expected Dividend Yield—The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

 

Expected Volatility—Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company’s initial public offering, there was not a market for the Company’s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company’s historical volatility since its initial public offering, to determine its expected volatility.

 

Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.

 

Expected Term—This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.

 

Expected Forfeiture Rate—The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.

 

Equity instruments issued to nonemployees are accounted for under the provisions of ASC 718, Compensation—Stock Compensation, and ASC 505-50, Equity—Equity-Based Payments to Non-Employees. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services are completed and are marked to market during the service period. 

 

Net Loss Per Common Share

 

Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock options, restricted stock units and warrants.

 

Basic and diluted net loss per common share is computed as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

    

2016

 

2015

    

Net loss

 

$

(7,854,693)

 

$

(7,168,071)

 

$

(23,481,241)

 

$

(3,887,795)

 

Basic and diluted net loss per common share

 

$

(0.34)

 

$

(0.38)

 

$

(1.14)

 

$

(0.20)

 

Basic and diluted weighted average common shares outstanding

 

 

23,049,347

 

 

19,025,623

 

 

20,638,129

 

 

18,999,705

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

    

2015

    

2016

    

2015

    

Warrants

 

555,412

 

590,595

 

555,412

 

590,595

 

Stock options and restricted stock units

 

2,815,166

 

2,250,008

 

2,815,166

 

2,250,008

 

 

Comprehensive Loss

 

Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and nine months ended September 30, 2016 and 2015, the Company’s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.  

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2016
Prepaid Expenses and Other Current Assets  
Prepaid Expenses and Other Current Assets

3. Prepaid Expenses and Other Current Assets

 

The following is a summary of the Company’s prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Prepaid expenses

 

$

667,644

 

$

393,857

 

Other receivables

 

 

572,072

 

 

38,683

 

Deposits

 

 

 —

 

 

9,270

 

Prepaid expenses and other current assets

 

$

1,239,716

 

$

441,810

 

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment
9 Months Ended
Sep. 30, 2016
Property and Equipment  
Property and Equipment

4. Property and Equipment

 

Property and equipment, net consists of the following:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Furniture and fixtures

 

$

230,987

 

$

230,987

 

Laboratory equipment

 

 

978,511

 

 

965,586

 

Office equipment

 

 

9,723

 

 

9,723

 

Computer equipment

 

 

186,172

 

 

181,053

 

Leasehold improvements

 

 

36,128

 

 

36,128

 

Construction in progress

 

 

271,355

 

 

 —

 

Property and equipment

 

 

1,712,876

 

 

1,423,477

 

Less accumulated depreciation

 

 

(1,036,283)

 

 

(902,099)

 

Property and equipment, net

 

$

676,593

 

$

521,378

 

Depreciation expense was $45,808 and $51,882 for the three months ended September 30, 2016 and 2015, respectively, and $139,749 and $142,417 for the nine months ended September 30, 2016 and 2015, respectively.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses
9 Months Ended
Sep. 30, 2016
Accrued Expenses  
Accrued Expenses

5. Accrued Expenses

 

The following is a summary of the Company’s accrued expenses:

 

 

 

 

 

 

 

 

 

 

    

September 30, 

    

December 31, 

 

 

 

2016

 

2015

 

Accrued research and development expenses

 

$

2,323,255

 

$

3,423,220

 

Accrued license and milestone fees

 

 

 —

 

 

2,000,000

 

Accrued consulting and other professional fees

 

 

263,211

 

 

242,227

 

Other accrued expenses

 

 

327,018

 

 

281,152

 

Accrued employee benefits

 

 

349,875

 

 

195,442

 

Accrued franchise and other taxes

 

 

 —

 

 

3,590

 

Accrued expenses

 

$

3,263,359

 

$

6,145,631

 

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Operating Leases
9 Months Ended
Sep. 30, 2016
Operating Leases  
Operating Leases

6. Operating Leases

 

The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances. In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease.

 

In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space as of June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance reflected in the Company’s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company’s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company’s renewal option set forth in the Lease. The Company’s one-time option to terminate the Lease effective as of October 31, 2020 also applies to the additional space.

 

Deferred rent related to the Lease was $922,824 and $243,647 at September 30, 2016 and December 31, 2015, respectively. Total rent expense under the Company’s operating leases was $219,983 and $216,765 for the three months ended September 30, 2016 and 2015, respectively, and $557,262 and $437,125 for the nine months ended September 30, 2016 and 2015, respectively.

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2016
Stockholders' Equity  
Disclosure of stockholders' equity and share-based compensation

7. Stockholders’ Equity

 

At-The-Market Equity Offering

 

On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company’s securities under a shelf registration statement filed in March 2015. As of September 30, 2016, the Company had issued and sold 483,298 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.296, for aggregate net proceeds of $2.7 million, after deducting commissions and offering expenses.

 

Equity Offering

 

In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share. The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.

 

2003 Stock Incentive Plan

 

The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60 days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May 21, 2013.

 

A summary of the Company’s stock option activity under the 2003 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

 

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

    

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

758,187

 

$

1.27

 

4.2

 

 

 

 

Options exercised

 

(27,268)

 

 

1.49

 

 

 

 

 

 

Options forfeited

 

 —

 

 

 —

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

730,919

 

 

1.26

 

3.5

 

$

4,306

 

Vested or expected to vest as of September 30, 2016

 

730,888

 

 

1.26

 

3.5

 

$

4,306

 

Exercisable as of September 30, 2016

 

729,565

 

 

1.25

 

3.5

 

$

4,301

 

 

As of September 30, 2016, there was $2,991 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over a weighted-average period less than one year. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 and 2015 was $95,221 and $699,196, respectively, and total cash received for options exercised was $40,668 and $110,697 during the nine months ended September 30, 2016 and 2015, respectively. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $14,450 and $38,223, respectively.

 

2013 Equity Incentive Plan

 

The Company’s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to the Company’s employees and its parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company’s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options will terminate 90 days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant.

 

Authorized Shares

 

The maximum number of shares of common stock that initially could be issued under the 2013 Plan was    1,000,000 shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan automatically increases on January 1 of each year until January 1, 2023, by 3% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company’s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January 1, 2016, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 571,506 shares, representing 3% of the total number of shares of common stock outstanding on December 31, 2015, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,139,701 shares.

 

Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan.

 

A summary of the Company’s stock option activity under the 2013 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

ccc

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

 

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

1,470,338

 

$

8.26

 

8.5

 

 

 

 

Options granted

 

618,250

 

 

5.35

 

 

 

 

 

 

Options exercised

 

(3,500)

 

 

7.95

 

 

 

 

 

 

Options forfeited

 

(22,591)

 

 

6.20

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

2,062,497

 

 

7.41

 

8.2

 

$

1,110

 

Vested or expected to vest as of September 30, 2016

 

2,053,321

 

 

7.41

 

8.2

 

$

1,100

 

Exercisable as of September 30, 2016

 

828,814

 

 

8.26

 

7.7

 

$

1

 

 

The weighted-average fair value of the options granted during the nine months ended September 30, 2016 and 2015 was $3.38 per share and $5.09 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions:

 

 

 

 

 

 

 

 

Nine Months Ended

 

Nine Months Ended

 

    

September 30, 2016

 

September 30, 2015

Expected term

 

6.25 years

 

6.25 years

Expected volatility

 

68.86%

 

80.83%

Risk-free interest rate

 

1.69%

 

1.70%

Expected dividend yield

 

0%

 

0%

 

As of September 30, 2016, there was $5,014,309 of total unrecognized compensation expense related to unvested options under the 2013 Plan that will be recognized over a weighted-average period of approximately 2.2 years. Total intrinsic value of the options exercised during the nine months ended September 30, 2016 was $2,275 and total cash received for options exercised was $27,825 during the nine months ended September 30, 2016. There were no options exercised during the nine months ending September 30, 2015. The total fair value of shares underlying options which vested in the nine months ended September 30, 2016 and 2015 was $2,364,683 and $2,314,557, respectively.

 

A restricted stock unit (RSU) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of September 30, 2016, there was $70,027 of unrecognized compensation costs related to unvested service RSUs.

 

The following is a summary of RSU activity under the 2013 Plan for the nine months ended September 30, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

NUMBER

 

GRANT DATE

 

 

    

OF SHARES

 

 

FAIR VALUE

 

Unvested at December 31, 2015

 

 

4,833

 

$

7.62

 

Granted

 

 

14,500

 

 

4.61

 

Forfeited

 

 

 —

 

 

 —

 

Vested

 

 

 —

 

 

 —

 

Unvested at September 30, 2016

 

 

19,333

 

 

5.36

 

 

Stock-based compensation expense was classified on the statement of operations as follows for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

   

2016

 

2015

    

Research and development expense

 

$

260,882

 

$

209,359

 

$

772,163

 

$

590,633

 

General and administrative expense

 

 

478,531

 

 

423,565

 

 

1,466,484

 

 

1,088,035

 

Total stock-based compensation expense

 

$

739,413

 

$

632,924

 

$

2,238,647

 

$

1,678,668

 

 

Warrants to Acquire Common Stock

 

During the three months ended September 30, 2016,  22,367 shares of common stock were issued to an existing stockholder upon the net exercise of a warrant.  No warrants were exercised during the three months ended September 30, 2015.  No warrants expired during the three months ended September 30, 2016 and 2015.

 

 

 

 

 

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
9 Months Ended
Sep. 30, 2016
Income Taxes  
Income Taxes

8. Income Taxes

 

The Company has not recorded any tax provision or benefit for the nine months ended September 30, 2016 and 2015. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at September 30, 2016 and December 31, 2015.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Research and License Agreements
9 Months Ended
Sep. 30, 2016
Revenue Recognition [Abstract]  
Research And License Agreements [Text Block]

9. Research and License Agreements

 

In October 2011, the Company and Pfizer entered into the Pfizer Agreement that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 clinical trial, after which Pfizer assumed all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Agreement by giving prior written notice.

 

The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-front payment was recognized over a period of 1.5 years. In May 2014, Pfizer made a $15.0 million non-refundable milestone payment to the Company, which was recognized as revenue by the Company in May 2014 when earned.  In June 2015, Pfizer dosed the first patient in the Phase 3 clinical trial of rivipansel, which triggered a non-refundable milestone payment to the Company of $20.0 million, which the Company recognized as revenue in June 2015.

 

In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe to the University 10% of all future milestone and royalty payments received from Pfizer with respect to rivipansel.  As of December 31, 2015, a $2.0 million milestone license fee was recorded as an accrued liability representing 10% of the $20.0 million non-refundable milestone payment that the Company received from Pfizer in 2015.  The accrued liability of $2.0 million was paid in February 2016.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2016
Summary of Significant Accounting Policies  
Basis of Accounting

Basis of Accounting

 

The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).

Unaudited interim financial statements

Unaudited Financial Statements

 

The accompanying balance sheet as of September 30, 2016 and statements of operations and comprehensive loss for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations for the United States Securities and Exchange Commission (the SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2015 contained in the Company’s Annual Report on Form 10-K filed with the SEC on February 29, 2016. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2016, the results of operations for the three and nine months ended September 30, 2016 and 2015 and cash flows for the nine months ended September 30, 2016 and 2015. The December 31, 2015 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2016 and 2015 are unaudited. Interim results are not necessarily indicative of results for an entire year.

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.

Fair Value Measurements

Fair Value Measurements

 

The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of September 30, 2016 and December 31, 2015. The carrying value of cash held in money market funds of approximately $44.1 million and $45.5 million as of September 30, 2016 and December 31, 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).

Concentration of Credit Risk

Concentration of Credit Risk

 

Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of money market funds with major financial institutions in the United States. These funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.

Revenue Recognition

Revenue Recognition

 

From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements.

 

The Company has entered into a collaborative research and development agreement with Pfizer Inc. (Pfizer). The agreement is in the form of a license agreement (the Pfizer Agreement). The Pfizer Agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The Pfizer Agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the Pfizer Agreement that contain material financial consequences to the Company.

 

The primary deliverable under this arrangement is an exclusive worldwide license to the Company’s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer’s behalf.

 

Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of Accounting Standards Codification (ASC) 605-25, Revenue Recognition—Multiple-Element Arrangements, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis and (2) if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i) vendor-specific objective evidence (VSOE), if available; (ii) third-party evidence (TPE) of selling price if VSOE is not available; or (iii) an estimated selling price, if neither VSOE nor TPE is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering into such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer Agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company’s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data.

 

Pursuant to ASC 605-25, each required deliverable under the Pfizer Agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company’s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company’s technology and the related proprietary nature of the Company’s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the Pfizer Agreement and will be combined with the research and development services (including participation on a joint steering committee).

 

As such, the $22.5 million up-front payment received was recognized as revenue over the expected development period through March 2013. The determination of the length of the period over which to defer revenue and the methodology by which to recognize the related revenues is subject to judgment and estimation. Consistent with the research plan developed by and agreed to by both parties, management estimated that the research activities and participation on the joint steering committees would occur over a 1.5-year period. Revenues associated with the up-front license fee were recognized over this period using a straight-line method, which was consistent with expected completion of the research services. The research services were completed in March 2013, consistent with the expected development period.

 

Pursuant to ASC 605-28, Revenue Recognition—Milestone Method, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement.

 

Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company’s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment.

Accrued Liabilities

Accrued Liabilities

 

The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company’s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company’s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company’s judgment.

Research and Development Costs

Research and Development Costs

 

Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations.

Stock-Based Compensation

Stock-Based Compensation

 

Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.

 

The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model.

 

A discussion of management’s methodology for developing some of the assumptions used in the valuation model follows:

 

Expected Dividend Yield—The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.

 

Expected Volatility—Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company’s initial public offering, there was not a market for the Company’s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company’s historical volatility since its initial public offering, to determine its expected volatility.

 

Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.

 

Expected Term—This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term.

 

Expected Forfeiture Rate—The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.

 

Equity instruments issued to nonemployees are accounted for under the provisions of ASC 718, Compensation—Stock Compensation, and ASC 505-50, Equity—Equity-Based Payments to Non-Employees. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services are completed and are marked to market during the service period.

Net (Loss) Income Per Common Share

Net Loss Per Common Share

 

Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock options, restricted stock units and warrants.

 

Basic and diluted net loss per common share is computed as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

    

2016

 

2015

    

Net loss

 

$

(7,854,693)

 

$

(7,168,071)

 

$

(23,481,241)

 

$

(3,887,795)

 

Basic and diluted net loss per common share

 

$

(0.34)

 

$

(0.38)

 

$

(1.14)

 

$

(0.20)

 

Basic and diluted weighted average common shares outstanding

 

 

23,049,347

 

 

19,025,623

 

 

20,638,129

 

 

18,999,705

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

    

2015

    

2016

    

2015

    

Warrants

 

555,412

 

590,595

 

555,412

 

590,595

 

Stock options and restricted stock units

 

2,815,166

 

2,250,008

 

2,815,166

 

2,250,008

 

 

Comprehensive Loss

 

Comprehensive Loss

 

Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three and nine months ended September 30, 2016 and 2015, the Company’s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Accounting Policies - 10-Q (Tables)
9 Months Ended
Sep. 30, 2016
Net Loss Per Share of Common Stock  
Computation of Basic and Diluted Earnings Per Share

Basic and diluted net loss per common share is computed as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

    

2016

 

2015

    

Net loss

 

$

(7,854,693)

 

$

(7,168,071)

 

$

(23,481,241)

 

$

(3,887,795)

 

Basic and diluted net loss per common share

 

$

(0.34)

 

$

(0.38)

 

$

(1.14)

 

$

(0.20)

 

Basic and diluted weighted average common shares outstanding

 

 

23,049,347

 

 

19,025,623

 

 

20,638,129

 

 

18,999,705

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potentially Dilutive Securities Outstanding

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average common shares outstanding, as they would be anti-dilutive:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

    

2015

    

2016

    

2015

    

Warrants

 

555,412

 

590,595

 

555,412

 

590,595

 

Stock options and restricted stock units

 

2,815,166

 

2,250,008

 

2,815,166

 

2,250,008

 

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2016
Prepaid Expenses and Other Current Assets  
Summary of Prepaid Expenses and Other Current Assets

The following is a summary of the Company’s prepaid expenses and other current assets:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Prepaid expenses

 

$

667,644

 

$

393,857

 

Other receivables

 

 

572,072

 

 

38,683

 

Deposits

 

 

 —

 

 

9,270

 

Prepaid expenses and other current assets

 

$

1,239,716

 

$

441,810

 

 

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Tables)
9 Months Ended
Sep. 30, 2016
Property and Equipment  
Summary of Property and Equipment, Net

Property and equipment, net consists of the following:

 

 

 

 

 

 

 

 

 

 

 

September 30, 

 

December 31, 

 

 

    

2016

    

2015

 

Furniture and fixtures

 

$

230,987

 

$

230,987

 

Laboratory equipment

 

 

978,511

 

 

965,586

 

Office equipment

 

 

9,723

 

 

9,723

 

Computer equipment

 

 

186,172

 

 

181,053

 

Leasehold improvements

 

 

36,128

 

 

36,128

 

Construction in progress

 

 

271,355

 

 

 —

 

Property and equipment

 

 

1,712,876

 

 

1,423,477

 

Less accumulated depreciation

 

 

(1,036,283)

 

 

(902,099)

 

Property and equipment, net

 

$

676,593

 

$

521,378

 

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2016
Accrued Expenses  
Summary of Accrued Expenses

 

 

 

 

 

 

 

 

 

 

    

September 30, 

    

December 31, 

 

 

 

2016

 

2015

 

Accrued research and development expenses

 

$

2,323,255

 

$

3,423,220

 

Accrued license and milestone fees

 

 

 —

 

 

2,000,000

 

Accrued consulting and other professional fees

 

 

263,211

 

 

242,227

 

Other accrued expenses

 

 

327,018

 

 

281,152

 

Accrued employee benefits

 

 

349,875

 

 

195,442

 

Accrued franchise and other taxes

 

 

 —

 

 

3,590

 

Accrued expenses

 

$

3,263,359

 

$

6,145,631

 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders Equity (Tables)
9 Months Ended
Sep. 30, 2016
Stock-Based Compensation Expense

Stock-based compensation expense was classified on the statement of operations as follows for the three and nine months ended September 30, 2016 and 2015:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

 

    

2016

 

2015

   

2016

 

2015

    

Research and development expense

 

$

260,882

 

$

209,359

 

$

772,163

 

$

590,633

 

General and administrative expense

 

 

478,531

 

 

423,565

 

 

1,466,484

 

 

1,088,035

 

Total stock-based compensation expense

 

$

739,413

 

$

632,924

 

$

2,238,647

 

$

1,678,668

 

 

2003 Stock Incentive Plan  
Company's Stock Option Activity

A summary of the Company’s stock option activity under the 2003 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

 

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

    

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

758,187

 

$

1.27

 

4.2

 

 

 

 

Options exercised

 

(27,268)

 

 

1.49

 

 

 

 

 

 

Options forfeited

 

 —

 

 

 —

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

730,919

 

 

1.26

 

3.5

 

$

4,306

 

Vested or expected to vest as of September 30, 2016

 

730,888

 

 

1.26

 

3.5

 

$

4,306

 

Exercisable as of September 30, 2016

 

729,565

 

 

1.25

 

3.5

 

$

4,301

 

 

2013 Equity Incentive Plan  
Company's Stock Option Activity

A summary of the Company’s stock option activity under the 2013 Plan for the nine months ended September 30, 2016 is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

ccc

 

 

 

WEIGHTED-

 

REMAINING

 

AGGREGATE

 

 

 

OUTSTANDING

 

AVERAGE

 

CONTRACTUAL TERM

 

INTRINSIC VALUE

 

 

 

OPTIONS

    

EXERCISE PRICE

    

(YEARS)

    

(IN THOUSANDS)

 

Outstanding as of December 31, 2015

 

1,470,338

 

$

8.26

 

8.5

 

 

 

 

Options granted

 

618,250

 

 

5.35

 

 

 

 

 

 

Options exercised

 

(3,500)

 

 

7.95

 

 

 

 

 

 

Options forfeited

 

(22,591)

 

 

6.20

 

 

 

 

 

 

Outstanding as of September 30, 2016

 

2,062,497

 

 

7.41

 

8.2

 

$

1,110

 

Vested or expected to vest as of September 30, 2016

 

2,053,321

 

 

7.41

 

8.2

 

$

1,100

 

Exercisable as of September 30, 2016

 

828,814

 

 

8.26

 

7.7

 

$

1

 

 

Weighted-Average Fair Value of Options Granted

 

 

 

 

 

 

 

 

Nine Months Ended

 

Nine Months Ended

 

    

September 30, 2016

 

September 30, 2015

Expected term

 

6.25 years

 

6.25 years

Expected volatility

 

68.86%

 

80.83%

Risk-free interest rate

 

1.69%

 

1.70%

Expected dividend yield

 

0%

 

0%

 

Summary of RSU Activity

The following is a summary of RSU activity under the 2013 Plan for the nine months ended September 30, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

WEIGHTED-AVERAGE

 

 

 

 

NUMBER

 

GRANT DATE

 

 

    

OF SHARES

 

 

FAIR VALUE

 

Unvested at December 31, 2015

 

 

4,833

 

$

7.62

 

Granted

 

 

14,500

 

 

4.61

 

Forfeited

 

 

 —

 

 

 —

 

Vested

 

 

 —

 

 

 —

 

Unvested at September 30, 2016

 

 

19,333

 

 

5.36

 

 

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - 10-Q (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 18 Months Ended
Jun. 30, 2015
May 31, 2014
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Mar. 31, 2013
Dec. 31, 2015
Share-based Compensation                
Expected term (years)         6 years 3 months      
Net (Loss) Income Per Common Share                
Net loss     $ (7,854,693) $ (7,168,071) $ (23,481,241) $ (3,887,795)    
Basic and diluted net loss per common share (in dollars per share)     $ (0.34) $ (0.38) $ (1.14) $ (0.20)    
Basic and diluted weighted average common shares outstanding     23,049,347 19,025,623 20,638,129 18,999,705    
Level 1                
Fair Value Measurements                
Carrying value of cash held in money market fund     $ 44,100,000   $ 44,100,000     $ 45,500,000
Level 2                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     0   0     0
Level 3                
Fair Value Measurements                
Assets measured at fair value levels 2 or 3     0   0     0
Liabilities measured at fair value levels 2 or 3     $ 0   $ 0     $ 0
Maximum                
Share-based Compensation                
Expiration period         10 years      
Warrants [Member]                
Net (Loss) Income Per Common Share                
Anti-dilutive securities     555,412 590,595 555,412 590,595    
Stock Options and Restricted Stock Units [Member]                
Net (Loss) Income Per Common Share                
Anti-dilutive securities     2,815,166 2,250,008 2,815,166 2,250,008    
Pfizer | License Agreement | Up-Front Payment Arrangement                
Revenue Recognition                
Upfront payment revenue recognized             $ 22,500,000  
Recognition period of up-front payment             1 year 6 months  
Achievement Of Specified Development Milestone | Pfizer | License Agreement                
Revenue Recognition                
Milestone revenue $ 20,000,000 $ 15,000,000            
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Prepaid Expenses and Other Current Assets    
Prepaid expenses $ 667,644 $ 393,857
Other receivables 572,072 38,683
Deposits   9,270
Prepaid expenses and other current assets $ 1,239,716 $ 441,810
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Property, Plant and Equipment [Line Items]          
Property and equipment $ 1,712,876   $ 1,712,876   $ 1,423,477
Less accumulated depreciation (1,036,283)   (1,036,283)   (902,099)
Property and equipment, net 676,593   676,593   521,378
Depreciation of property and equipment 45,808 $ 51,882 139,749 $ 142,417  
Furniture and Fixtures [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment 230,987   230,987   230,987
Laboratory Equipment [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment 978,511   978,511   965,586
Office Equipment [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment 9,723   9,723   9,723
Computer Equipment [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment 186,172   186,172   181,053
Leasehold Improvements [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment 36,128   36,128   $ 36,128
Construction in Progress [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 271,355   $ 271,355    
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Accrued Expenses    
Accrued research and development expenses $ 2,323,255 $ 3,423,220
Accrued license and milestone fees   2,000,000
Accrued consulting and other professional fees 263,211 242,227
Other accrued expenses 327,018 281,152
Accrued employee benefits 349,875 195,442
Accrued franchise and other taxes   3,590
Accrued expenses $ 3,263,359 $ 6,145,631
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Operating Leases - 10Q (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
May 31, 2016
Dec. 31, 2015
Deferred Rent Credit $ 922,824   $ 922,824     $ 243,647
Operating leases, rent expense 219,983 $ 216,765 557,262 $ 437,125    
Deposits $ 52,320   $ 52,320      
Rockville            
Deposits         $ 52,320  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Equity Offerings (Detail) - USD ($)
1 Months Ended 7 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2016
Equity offerings      
Aggregate net proceeds from stock sale     $ 22,453,785
At The Market Equity Offering | Common Stock      
Equity offerings      
Issuance of common stock, net of issuance costs, shares   483,298  
Weighted average price per share issued   $ 6.296 $ 6.296
Aggregate net proceeds from stock sale   $ 2,700,000  
Public Equity Offering | Common Stock      
Equity offerings      
Issuance of common stock, net of issuance costs, shares 3,476,793    
Weighted average price per share issued $ 6.10    
Aggregate net proceeds from stock sale $ 19,700,000    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Incentive Plans (Detail) - USD ($)
9 Months Ended
Jan. 01, 2016
Jan. 09, 2014
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Incentive plans          
Options exercised       0  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period       0  
Maximum          
Incentive plans          
Expiration period     10 years    
2003 Stock Incentive Plan          
Incentive plans          
Period from date of termination that any vested options shall expire     60 days    
Expiration period     10 years    
Unrecognized compensation expense related to unvested options     $ 2,991    
Period for unrecognized compensation expense related to unvested options yet has not been recognized     1 year    
Intrinsic value of options exercised     $ 95,221 $ 699,196  
Cash proceeds from exercise of stock options     $ 40,668 110,697  
Options exercised     27,268    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period     27,268    
Fair value of shares vested     $ 14,450 38,223  
2003 Stock Incentive Plan | Upon first anniversary of start date          
Incentive plans          
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage     25.00%    
2003 Stock Incentive Plan | Each month after the first anniversary          
Incentive plans          
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage     2.083%    
2013 Equity Incentive Plan          
Incentive plans          
Period from date of termination that any vested options shall expire   90 days      
Expiration period   10 years      
Unrecognized compensation expense related to unvested options     $ 5,014,309    
Period for unrecognized compensation expense related to unvested options yet has not been recognized     2 years 2 months 12 days    
Intrinsic value of options exercised     $ 2,275    
Cash proceeds from exercise of stock options     $ 27,825    
Options exercised     3,500    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period     3,500    
Fair value of shares vested     $ 2,364,683 $ 2,314,557  
2013 Equity Incentive Plan | Upon first anniversary of start date          
Incentive plans          
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage   25.00%      
2013 Equity Incentive Plan | Each month after the first anniversary          
Incentive plans          
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage   2.083%      
Common Stock | 2013 Equity Incentive Plan          
Authorized shares          
Common stock authorized under 2013 plan 2,139,701 1,000,000      
Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year   3.00%     3.00%
Maximum number of shares that may be issued pursuant to exercise of incentive stock   20,000,000      
Increase in number of shares of common stock 571,506        
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Company's Stock Option Activity (Detail) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
OUTSTANDING OPTIONS      
Options exercised   0  
2003 Stock Incentive Plan      
OUTSTANDING OPTIONS      
Outstanding at beginning of period 758,187    
Options exercised (27,268)    
Outstanding at end of period 730,919   758,187
WEIGHTED-AVERAGE EXERCISE PRICE      
Outstanding at beginning of period $ 1.27    
Options exercised 1.49    
Outstanding at end of period $ 1.26   $ 1.27
VESTED AND EXPECTED TO VEST      
Outstanding options 730,888    
Weighted-Average Exercise Price $ 1.26    
Weighted-Average Remaining Contractual Term 3 years 6 months    
Aggregate Intrinsic Value (in thousands) $ 4,306    
ADDITIONAL DISCLOSURES      
Outstanding options exercisable at end of period 729,565    
Weighted-average exercise price exercisable at end of period $ 1.25    
Weighted-average contractual term (years) exercisable at end of period 3 years 6 months    
Aggregate intrinsic value (in thousands) exercisable at end of period $ 4,301    
Weighted-average contractual term outstanding 3 years 6 months   4 years 2 months 12 days
Aggregate intrinsic value (in thousands) outstanding at end of period $ 4,306    
2013 Equity Incentive Plan      
OUTSTANDING OPTIONS      
Outstanding at beginning of period 1,470,338    
Options granted 618,250    
Options exercised (3,500)    
Options forfeited (22,591)    
Outstanding at end of period 2,062,497   1,470,338
WEIGHTED-AVERAGE EXERCISE PRICE      
Outstanding at beginning of period $ 8.26    
Options granted 5.35    
Options exercised 7.95    
Options forfeited 6.20    
Outstanding at end of period $ 7.41   $ 8.26
VESTED AND EXPECTED TO VEST      
Outstanding options 2,053,321    
Weighted-Average Exercise Price $ 7.41    
Weighted-Average Remaining Contractual Term 8 years 2 months 12 days    
Aggregate Intrinsic Value (in thousands) $ 1,100    
ADDITIONAL DISCLOSURES      
Outstanding options exercisable at end of period 828,814    
Weighted-average exercise price exercisable at end of period $ 8.26    
Weighted-average contractual term (years) exercisable at end of period 7 years 8 months 12 days    
Aggregate intrinsic value (in thousands) exercisable at end of period $ 1    
Aggregate intrinsic value (in thousands) outstanding at end of period $ 1,110    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Weighted-Average assumptions (Detail) - $ / shares
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Weighted-average assumptions    
Expected term (years) 6 years 3 months  
2013 Equity Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted-average fair value of the options granted $ 3.38 $ 5.09
Weighted-average assumptions    
Expected term (years) 6 years 3 months 6 years 3 months
Expected volatility 68.86% 80.83%
Risk-free interest rate 1.69% 1.70%
Expected dividend yield 0.00% 0.00%
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Summary of RSU Activity (Detail) - RSU [Member] - 2013 Equity Incentive Plan
9 Months Ended
Sep. 30, 2016
USD ($)
installment
$ / shares
shares
Restricted Stock Units information  
Unrecognized compensation expense related to unvested service RSUs | $ $ 70,027
Number of vesting installments | installment 3
NUMBER OF SHARES  
Unvested at beginning of period | shares 4,833
Granted | shares 14,500
Forfeited | shares 0
Vested | shares 0
Unvested at end of period | shares 19,333
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE  
Unvested at beginning of period | $ / shares $ 7.62
Granted | $ / shares 4.61
Forfeited | $ / shares 0.00
Vested | $ / shares 0.00
Unvested at end of period | $ / shares $ 5.36
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Stock-based compensation expense        
Total stock-based compensation expense $ 739,413 $ 632,924 $ 2,238,647 $ 1,678,668
Warrants to Acquire Company Stock        
Common stock issued at exercise of warrants 22,367      
Number of warrants exercised   0    
Number of warrants expired 0 0    
Research and Development        
Stock-based compensation expense        
Total stock-based compensation expense $ 260,882 $ 209,359 772,163 590,633
General and Administrative Expense        
Stock-based compensation expense        
Total stock-based compensation expense $ 478,531 $ 423,565 $ 1,466,484 $ 1,088,035
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes - 10-Q (Details) - USD ($)
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Income Taxes    
Income tax (benefit) provision $ 0 $ 0
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Research and License Agreements - Additional Information (Detail)
1 Months Ended 9 Months Ended 18 Months Ended
Feb. 29, 2016
USD ($)
Jun. 30, 2015
USD ($)
May 31, 2014
USD ($)
Oct. 31, 2011
USD ($)
item
Sep. 30, 2016
Mar. 31, 2013
USD ($)
Dec. 31, 2015
USD ($)
Research and License Agreements              
Milestone license fee liability             $ 2,000,000
License Agreement | Pfizer | Up-Front Payment Arrangement              
Research and License Agreements              
Upfront payment received       $ 22,500,000      
Upfront payment revenue recognized           $ 22,500,000  
Recognition period of up-front payment           1 year 6 months  
Research Services Agreement | University Of Basel              
Research and License Agreements              
Royalty payment due against license fees received (as a percent)         10.00%    
Milestone license fee liability             $ 2,000,000
Payment of milestone liability $ 2,000,000            
Achievement Of Specified Development Milestone | License Agreement | Pfizer              
Research and License Agreements              
Number of indications | item       2      
Milestone revenue   $ 20,000,000 $ 15,000,000        
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum              
Research and License Agreements              
Potential milestone payments       $ 115,000,000      
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer              
Research and License Agreements              
Number of indications | item       2      
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum              
Research and License Agreements              
Potential milestone payments       $ 70,000,000      
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum              
Research and License Agreements              
Potential milestone payments       $ 135,000,000      
EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 81 171 1 false 31 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://glyc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://glyc.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00205 - Statement - Balance Sheets (Parenthetical) Sheet http://glyc.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00300 - Statement - Statements of Operations and Comprehensive Loss Sheet http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00500 - Statement - Statements of Cash Flows Sheet http://glyc.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - Description of the Business Sheet http://glyc.com/role/DisclosureDescriptionOfBusiness Description of the Business Notes 6 false false R7.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 10301 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 8 false false R9.htm 10401 - Disclosure - Property and Equipment Sheet http://glyc.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 10501 - Disclosure - Accrued Expenses Sheet http://glyc.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 10 false false R11.htm 10601 - Disclosure - Operating Leases Sheet http://glyc.com/role/DisclosureOperatingLeases Operating Leases Notes 11 false false R12.htm 10701 - Disclosure - Stockholders' Equity Sheet http://glyc.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 10801 - Disclosure - Income Taxes Sheet http://glyc.com/role/DisclosureIncomeTaxes Income Taxes Notes 13 false false R14.htm 10901 - Disclosure - Research and License Agreements Sheet http://glyc.com/role/DisclosureResearchAndLicenseAgreements Research and License Agreements Notes 14 false false R15.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 30203 - Disclosure - Significant Accounting Policies - 10-Q (Tables) Sheet http://glyc.com/role/DisclosureSignificantAccountingPolicies10QTables Significant Accounting Policies - 10-Q (Tables) Tables 16 false false R17.htm 30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 17 false false R18.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://glyc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://glyc.com/role/DisclosurePropertyAndEquipment 18 false false R19.htm 30503 - Disclosure - Accrued Expenses (Tables) Sheet http://glyc.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://glyc.com/role/DisclosureAccruedExpenses 19 false false R20.htm 30703 - Disclosure - Stockholders Equity (Tables) Sheet http://glyc.com/role/DisclosureStockholdersEquityTables Stockholders Equity (Tables) Tables 20 false false R21.htm 40201 - Disclosure - Summary of Significant Accounting Policies - 10-Q (Details) Sheet http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies10QDetails Summary of Significant Accounting Policies - 10-Q (Details) Details http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 21 false false R22.htm 40301 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) Sheet http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) Details 22 false false R23.htm 40401 - Disclosure - Property and Equipment (Detail) Sheet http://glyc.com/role/DisclosurePropertyAndEquipmentDetail Property and Equipment (Detail) Details http://glyc.com/role/DisclosurePropertyAndEquipmentTables 23 false false R24.htm 40501 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) Sheet http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail Accrued Expenses - Summary of Accrued Expenses (Detail) Details 24 false false R25.htm 40601 - Disclosure - Operating Leases - 10Q (Details) Sheet http://glyc.com/role/DisclosureOperatingLeases10qDetails Operating Leases - 10Q (Details) Details 25 false false R26.htm 40701 - Disclosure - Stockholders' Equity - Equity Offerings (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquityEquityOfferingsDetail Stockholders' Equity - Equity Offerings (Detail) Details 26 false false R27.htm 40702 - Disclosure - Stockholders' Equity - Incentive Plans (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail Stockholders' Equity - Incentive Plans (Detail) Details 27 false false R28.htm 40703 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail Stockholders' Equity - Company's Stock Option Activity (Detail) Details 28 false false R29.htm 40704 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail Stockholders' Equity - Weighted-Average assumptions (Detail) Details 29 false false R30.htm 40705 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail Stockholders' Equity - Summary of RSU Activity (Detail) Details 30 false false R31.htm 40706 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail) Sheet http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail Stockholders' Equity - Stock-Based Compensation Expense (Detail) Details 31 false false R32.htm 40801 - Disclosure - Income Taxes - 10-Q (Details) Sheet http://glyc.com/role/DisclosureIncomeTaxes10QDetails Income Taxes - 10-Q (Details) Details 32 false false R33.htm 40901 - Disclosure - Research and License Agreements - Additional Information (Detail) Sheet http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail Research and License Agreements - Additional Information (Detail) Details 33 false false All Reports Book All Reports glyc-20160930.xml glyc-20160930.xsd glyc-20160930_cal.xml glyc-20160930_def.xml glyc-20160930_lab.xml glyc-20160930_pre.xml true true ZIP 50 0001558370-16-009291-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-16-009291-xbrl.zip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end